



iMig2023


LILLE GRAND PALAIS
FRANCE • JUNE 26 → 28

PROGRAM



www.iMig2023.org

#iMig2023



In 1922, **NELLIE KERSHAW** was the first person diagnosed with asbestosis. In 1924, she was the first known to die from it. In 1927, hers was the first published case report coining the term “asbestosis” describing the pathology and attributing occupational causation. [Cooke WE. Pulmonary asbestosis. British Medical Journal. 1927 Dec 12;2(3491):1024]

She began working with asbestos at age 13, and by 29 was too ill to work. Desperately fighting for her life, she wrote to her employer, Turner Brothers, asking:

“What are you going to do about my case? I have been home 9 weeks now and have not received a penny – I think it’s time that there was something from you as the National Health refuses to pay me anything. I am needing nourishment and the money, I should have had 9 weeks wages now through no fault of my own. ”

Turner Brothers refused and paid nothing. She died, impoverished, at age 33.

How much has changed? Knowledge and science have advanced. We now know a lot more about all the diseases asbestos causes; treatments have improved; victims are much better compensated. As lawyers we cannot heal people, but for almost 50 years we have helped them take comfort in knowing that when asbestos victims die their families will be taken care of. But people still die, asbestos is still used, and companies still seek to evade their responsibilities; they still lie. Johnson & Johnson tried to evade its responsibilities by manipulating the US court system, and after the Courts threw out that attempt, it responded, “There has never been asbestos in our baby powder; it’s completely safe.” Some things never change!

Kazan Law believes that our obligation to our clients – the families and the victims of asbestos-related diseases – and to society at large must go beyond providing legal services. We are committed to raising awareness about the dangers of asbestos as well as supporting regulatory efforts and social movements to ban asbestos use worldwide. Our firm strives to make a broader contribution to the mesothelioma community through support which includes:

- **Mesothelioma Research** – *The Kazan McClain Partners’ Foundation has funded almost \$10 million for mesothelioma research at leading medical facilities in the United States and elsewhere.*
- **Ban Asbestos** – *For the past 25 years, our Firm and its Foundation has been the major financial supporter of the International Ban Asbestos Secretariat, which coordinates the worldwide asbestos ban campaigns*
- **Young Investigator Awards** – *We are proud to have first proposed this important recognition of the junior scientists joining our mesothelioma community, and are honored to have funded it since it began in 2008*
- **ITONF** - *We have this year established a travel grant award program to fund attendance at iMig, and the affiliated nursing program, which we intend to continue for future iMig conference.*

So let us remember Nellie Kershaw and what her life and death has meant for the last 100 years.

Dear Colleagues,
BIENVENUE EN FRANCE !

On behalf of the International Mesothelioma Interest Group (iMig) and the French Cooperative Thoracic Intergroup (IFCT), it is a great pleasure and an honour to welcome you to Lille for the 16th International Conference of the International Mesothelioma Interest Group (iMig 2023).

Building on the experience and the success of previous great meetings since the founding of iMig in Paris in 1991, and as a collective effort by iMig and IFCT members, our multidisciplinary conference has brought together delegates from around the world and features the most up-to-date research on diverse topics of interest.

Thanks to our international Scientific Committee, the conference program includes major keynote speakers, excellent panelists, and a selection of the best submitted abstracts. Thus, through workshops, plenary sessions, oral abstracts, poster sessions and other events, this meeting will offer you plenty of networking opportunities with leading scientists and clinicians in mesothelioma field, with highly experienced nurses and allied health professionals, and also with patients and their associations. We hope that the resulting stimulating ideas will help to establish research collaborations and to fund projects.

We are very proud to host the 2023 iMig Conference in Lille, a modern city with friendly and beautiful traditions. This outstanding scientific event is an exciting time for mesothelioma research and the future of patient management.

We wish you all a great stay in Lille and an unforgettable conference!

Pr Arnaud Scherpereel, iMig 2023 Conference Chair, iMig President
Pr Virginie Westeel, IFCT President
Pr Jan van Meerbeeck, iMig 2023 Conference Co-Chair



ABOUT THE INTERNATIONAL MESOTHELIOMA INTEREST GROUP (iMig)

The international Mesothelioma interest group (iMig) is a community of physicians, basic researchers, scientists, care providers, and social advocates that is engaged in understanding the underlying genetics, immune and molecular mechanisms, proteomics, and epidemiologic factors associated with mesothelioma.

As not only the original and longest standing (1995), but the only society dedicated solely to the study of mesothelioma, iMig aims to be the central body promoting research, treatment, and education for mesothelioma.

iMig strives to play a central role in identifying and endorsing the best treatments available for mesothelioma patients today and establishing the best possible treatments for tomorrow.



ABOUT THE FRENCH COOPERATIVE THORACIC INTERGROUP (IFCT)

iMig 2023 Organizer on behalf of iMig
Established in 1999, the IFCT consolidates medical and scientific expertise in thoracic oncology, giving it the unique capacity to recruit patients for all phases of cancer treatment evaluation. The IFCT has its own operational infrastructure and is equipped to design, promote, and carry out clinical studies in France and internationally, and to communicate the findings thus obtained. The IFCT is a major player in clinical oncology research, with thousands of patients enrolled in investigations since its establishment, and findings published in the most highly recognized medical journals (Lancet, JCO, etc.). The IFCT's activity regularly results in the introduction of new drugs or strategies that improve the efficacy, safety, and/or economic impact of anti-cancer therapies. This in turn leads to better patient management. The IFCT also got involved since decade to develop translational research by associating systematically one or several studies with every decades clinical trial.



Summary

iMig CONFERENCE VENUES	4
LAYOUT PLAN	5


iMig PROGRAM OVERVIEW	6
------------------------------	---

iMig/ITONF MESO NURSE MEETING	
Sunday, June 25, 2023	13

iMig CONFERENCE	
Monday, June 26, 2023	14
Tuesday, June 27, 2023	18
Wednesday, June 28, 2023	22
Selected posters	27

FIND PRACTICAL INFORMATION AND ORGANIZE YOUR PROGRAM!

—
OFFICIAL CONGRESS APPLICATION
—

Scan me! 


WIFI
User : **IMIG2023**
Login : **astrazeneca**

Conference venues

June 26 -> 28
LILLE GRAND PALAIS
1 Boulevard des Cités Unies, Lille



Sunday, June 25
CONSEIL REGIONAL HAUTS DE FRANCE
151 Avenue du Président Hoover, Lille
Welcome Reception



Sunday, June 25
CHU LILLE INSTITUT COEUR POUMON
Boulevard du Professeur Jules Leclercq, Lille
Nurse Meeting



OVERVIEW



Monday, June 26, 2023

ROOMS	AMPHITHEATER GRAND THÉÂTRE	ROOM 2.3
7:30AM > 8:30AM	DELEGATES ARRIVAL	
8:30AM > 10:15AM	OPENING PLENARY SESSION 1 Welcome Speech  Epidemiology status and major pathogenesis breakthrough in Mesothelioma in 2023	
10:15AM > 11:00AM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
11:00AM > 12:45PM	PLENARY SESSION 2  Pathology classification, predictive biomarkers...: have we yet the right tools for discussing mesothelioma cases in MTB?	
12:45PM > 1PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
1PM > 2PM		Satellite meeting for patient associations - iMig Board Meeting (Room 2.1)
2PM > 2:15PM	COFFEE BREAK	
2:15PM > 3:45PM	WORKSHOP 3 Imaging (AI, diagnosis, staging...)	WORKSHOP 2 Focussing on patients experience: improving mesothelioma patients and relatives management
3:45PM > 4:30PM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
4:30PM > 6PM	WORKSHOP 5 Pathology advances and assessment of the tumor microenvironment	WORKSHOP 6 Mesothelioma pre-clinical models and results
6PM > 6:30PM		


ROOMS	ROOM 3.5	LE SQUARE AREA
7:30AM > 8:30AM	DELEGATES ARRIVAL	
8:30AM > 10:15AM		
10:15AM > 11:00AM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
11:00AM > 12:45PM		
12:45PM > 1PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
1PM > 2PM		POSTER VIEWING & BOOTH VISIT
2PM > 2:15PM	COFFEE BREAK	
2:15PM > 3:45PM	WORKSHOP 1 An international effort to standardize surgery for mesothelioma	
3:45PM > 4:30PM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
4:30PM > 6PM	WORKSHOP 4  From european Mesothelioma experience to european collaborative projects initiative (iMig/ETOP joint symposium)	
6PM > 6:30PM		POSTER MIXER & POSTER DISCUSSION SESSION 



Tuesday, June 27, 2023

ROOMS	AMPHITHEATER GRAND THÉÂTRE	ROOM 2.3
7:30AM > 8AM	DELEGATES ARRIVAL	
8AM > 9:30AM	PLENARY SESSION 3 Surgery, Radiotherapy, (neo)adjuvant therapies: what is the best combo for multimodal treatment?	
9:30AM > 10:15AM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
10:15AM > 11:45AM	YOUNG INVESTIGATORS Lessons and advice from previous iMig YI awardees and promising directions for mesothelioma research	
11:45AM > 12PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
12PM - 1PM	INDUSTRIAL SYMPOSIUM RS ONCOLOGY 	
1PM - 1:15PM	COFFEE BREAK	
1:15PM > 2:45PM	WORKSHOP 7  Immunotherapies: new drugs and strategies including cell therapies, and trials	WORKSHOP 9 Peritoneal Mesothelioma
2:45PM > 3:30PM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
3:30PM > 5PM	WORKSHOP 10 Mesothelioma biology and novel targets: from bench to bedside	WORKSHOP 12 Biomarkers, Genetics/Bioinformatics
5PM > 5:30PM		

FROM 7:00PM iMig GALA DINNER - LILLE ART MUSEUM (Palais des Beaux-Arts) including iMig medals & awards announcement.

ROOMS	ROOM 3.5	LE SQUARE AREA
7:30AM > 8AM	DELEGATES ARRIVAL	
8AM > 9:30AM		
9:30AM > 10:15AM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
10:15AM > 11:45PM		
11:45PM > 12PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
12PM - 1PM		POSTER VIEWING & BOOTH VISIT
1PM - 1:15PM	COFFEE BREAK	
1:15PM > 2:45PM	WORKSHOP 8 iMig/patient associations track: asbestos control, health promotion, advocacy, prevention and patients experience (MARF/iMig)	
2:45PM > 3:30PM	NETWORKING BREAK POSTER VIEWING & BOOTH VISIT	
3:30PM > 5PM	WORKSHOP 11 iMig/patient associations track: Focus on the patient experience: supportive care...	
5PM > 5:30PM		POSTER MIXER & POSTER DISCUSSION SESSION 

FROM 7:00PM iMig GALA DINNER - LILLE ART MUSEUM (Palais des Beaux-Arts) including iMig medals & awards announcement.



Wednesday, June 28, 2023

ROOMS	AMPHITHEATER GRAND THÉÂTRE	ROOM 2.3
8AM > 8:30AM	DELEGATES ARRIVAL	
8:30AM > 10AM	PLENARY SESSION 4 Not all patients die of Mesothelioma?! Exceptional survivals / cure results / perspectives	
10AM > 10:30AM	NETWORKING BREAK BOOTH VISIT	
10:30AM > 12PM	WORKSHOP 15 Is personalized medicine ready for prime time in Mesothelioma? 	WORKSHOP 14 Nurses and allied health: advances in Mesothelioma patients care
12PM > 12:45PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
12:45PM - 2:15PM	PLENARY SESSION 5 Joint iMig/IASLC session: Work in progress and what's next in Mesothelioma field?	
2:15PM > 2:30PM	PRESIDENTIAL CLOSING & SAVE THE DATE iMig 2025	

ROOMS	ROOM 3.5	LE SQUARE AREA
8AM > 8:30AM	DELEGATES ARRIVAL	
8:30AM > 10AM		
10AM > 10:30AM	NETWORKING BREAK BOOTH VISIT	
10:30AM > 12PM	WORKSHOP 13 Initial localized disease, oligoprogression: ready for changes in treatment paradigm?	
12PM > 12:45PM	LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES	
12:45PM - 2:15PM		
2:15PM > 2:30PM		



iMig BOARD MEMBERS

iMig 2023 LOCAL ORGANIZING COMMITTEE MEMBERS

Chair

Arnaud Scherpereel (Lille, France)

Co-Chair

Jan Van Meerbeeck (Antwerp, Belgium)

IFCT Président

Virginie Westeel (Besançon, France)

IFCT Board – France

Alexis Cortot (Lille), Etienne Giroux-Leprieur (Boulogne-Billancourt), Franck Morin (Paris), Gérard Zalcmán (Paris)

iMig EXECUTIVE BOARD MEMBERS

Africa

Jim teWaterNaude – iMig Treasurer (Cape Town, South Africa)

America

Sam Armato – immediate past-President (Chicago, USA), Raphael Bueno (New York City, USA), Marc de Perrot (Toronto, Canada), Joseph Friedberg (Philadelphia, USA), Hedy Kindler (Chicago, USA), Andreas Rimner (New York City, USA)

Asia

Takashi Nakano (Osaka, Japan), Yoshitaka Sekido (Nagoya, Japan)

Europe

Sjaak Burgers (Amsterdam, The Netherlands), Liz Darlison (Leicester, UK), Didier Jean (Paris, France), Arnaud Scherpereel (Lille, France; iMig President), Isabelle Schmitt Opitz (Zurich, Switzerland), Jeremy Steele (London, UK; iMig Secretary), Jan van Meerbeeck (Antwerp, Belgium)

Oceania

Anna Nowak (Perth, Australia), Ken O'Byrne (Brisbane, Australia), Bruce Robinson (Perth, Australia)

iMig 2023 SCIENTIFIC COMMITTEE MEMBERS

including iMig EXECUTIVE BOARD members

France

Fabrice Barlési (Villejuif)
 Christophe Blanquart (Nantes)
 Lynnette Fernandez-Cuesta (Lyon)
 Nicolas Girard (Paris)
 Olivier Glehen (Lyon)
 Laurent Greillier (Marseille)
 Didier Jean (Paris)
 Sylvie Lantuejoul (Lyon)
 Françoise Le Pimpec-Barthes (Paris)
 Julien Mazières (Toulouse)
 Arnaud Scherpereel (Lille)
 Nicolas Venissac (Lille)
 Virginie Westeel (Besançon)
 Gérard Zalcmán (Paris)

Netherlands

Joachim G.J.V. Aerts (Rotterdam)
 Paul Baas (Amsterdam)
 Sjaak Burgers (Amsterdam)

United Kingdom

Kevin Blyth (Glasgow)
 Corinne Faivre-Finn (Manchester)
 Dean Fennell (Leicester)
 Crispin Hiley (London)
 Astero Klampatsa (London)
 Nick Maskell (Bristol)
 Sanjay Popat (London)

Belgium

Thierry Berghmans (Brussels)
 Kristiaan Nackaerts (Leuven)
 Thierry Pieters (Brussels)
 Veerle Surmont (Ghent)
 Elisabeth Van Eycken (Brussels)
 Jen Van Meerbeeck (Antwerp)
 Paul Van Schil (Antwerp)
 Luc Willems (Brussels)

USA

Steven M. Albelda (Philadelphia)
 Michele Carbone (Hawaii)
 Melissa Culligan (Philadelphia)
 Sanja Dacic (New Haven)
 Arthur Frank (Philadelphia)
 Raffit Hassan (Bethesda)
 Daniel Serman (New-York City)
 Anne S. Tsao (Houston)
 Marjorie Zauderer (New-York City)

Switzerland

Solange Peters (Lausanne)

Australia

Jenette Creaney (Perth)
 Ken Takahashi (Sydney)

Sunday, June 25, 2023

11:30am-5:45pm | iMig/ITONF MESO NURSE MEETING

— 11:30am-3:05pm | **PLENARY SESSION 1** | INSTITUT COEUR POU MON

Working towards a greater understanding through rigorous research

Chairs: Liz DARLISON, UK & Melissa CULLIGAN, USA

11:30am > 12:15pm

Tour of hospital - CHU de Lille & Institut Coeur Poumon.

12:15pm > 1:00pm

Registration, lunch, exhibition & poster viewing.

1:00pm > 1:05pm

Opening & welcome to ITONF / iMig nursing workshop.

Arnaud SCHERPEREEL, France

1:05pm > 1:30pm

The story of a dedicated research team in mesothelioma.

Angela TOD & Bethany TAYLOR, UK

1:30pm > 1:50pm

Surviving mesothelioma in 2023: the latest and greatest treatment options.

Suzanne WALKER, USA

1:50pm > 2:35pm

Nursing abstracts in mesothelioma.

Discussant: Bethany TAYLOR, UK

2:35pm > 3:05pm

Afternoon tea - Meet the nurse researchers.

— 3:05pm-5:45pm | **PLENARY SESSION 2** | INSTITUT COEUR POU MON

Improving survivorship in mesothelioma

Chairs: Liz DARLISON, UK & Melissa CULLIGAN, USA

3:05pm > 3:25pm

Key elements of cancer survivorship.

Erica GLASS, USA

3:25pm > 3:50pm

Long term survivorship in mesothelioma.

Matthew JOHNSON, UK

3:50pm > 4:10pm

My journey with mesothelioma.

Helen BONE, UK

4:10pm > 4:50pm

Survivorship in mesothelioma: what does the future look like?

Led by Leah TAYLOR, UK

4:50pm > 5:00pm

Getting the most out of the iMig conference.

Led by Melissa CULLIGAN, USA

5:00pm > 5:10pm

Summary and close.

Mary DUFFY, co-chair ITONF, UK

5:10pm > 5:45pm

Networking reception.

FROM 6:30pm | **WELCOME RECEPTION - CONSEIL RÉGIONAL HAUTS-DE-FRANCE**

PROGRAM

Monday, June 26, 2023

7:30am-8:30am | DELEGATES ARRIVAL

— 8:30am-10:15am | **OPENING PLENARY SESSION 1** | AMPHITHEATER GRAND THÉÂTRE

Epidemiology status and major pathogenesis breakthrough in mesothelioma in 2023

Chairs: Françoise GALATEAU-SALLÉ, France; Jim TEWATERNAUDE, South Africa; Jan VAN MEERBEECK, Belgium

8:30am > 8:45am

Welcome speech and an overview of our lost colleagues' career in mesothelioma.

Arnaud SCHERPEREEL and Virginie WESTEEL, France; Sam ARMATO, USA

8:45am > 9:00am

Lecture 1: The global mesothelioma epidemic and control strategies in 2023.

Arthur L. FRANK, USA

9:00am > 9:15am

Lecture 2: Pleural and peritoneal mesotheliomas: two disease cousins but not sisters.

Vahan KEPENEKIAN, France

9:15am > 9:30am

Lecture 3: A general review on genomics advances - a single cell landscape of mesothelioma.

Jennette CREANEY, Australia

9:30am > 9:45am

Lecture 4: Mesothelioma, a BAP1 story.

Raffit HASSAN, USA

9:45am > 10:15am | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



10:15am-11:00am BREAK, POSTER VIEWING & BOOTH VISIT

—11:00am-12:45pm | **PLENARY 2** | AMPHITHEATER GRAND THÉÂTRE

Pathology classification, predictive biomarkers...: have we yet the right tools for discussing mesothelioma cases in MTB?

Chairs: Harvey PASS, USA; Anna NOWAK, Australia; Luana CALABRO, Italy

11:00am > 11:15am

Lecture 1: New entities and concepts of the 2021 WHO classification for mesothelioma.

Sonia KLEBE, Australia

11:15am > 11:45am

Pro/con debate: Immunotherapy is an established treatment in pleural mesothelioma based on clinical trials data.

Hedy KINDLER, USA and Luciano MUTTI, Italy

11:45am > 11:55am

Lecture 2: Optimizing immunotherapy in mesothelioma by in situ imaging: lessons from lung cancer experience.

Diane DAMOTTE, France

11:55am > 12:05pm

CO-024. Computational dissection of pleural mesothelioma identifies biomarkers to distinguish malignant sarcomatoid cells from benign mesenchymal stroma. David T. SEVERSON, USA

12:05pm > 12:15pm

CO-043. Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.

Dean FENNELL, UK

12:15pm > 12:45pm | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



12:45pm-1:00pm LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES

— 1:00pm-2:00pm | LUNCHEON BREAK IN THE ROOM

Satellite meeting for patient associations | ROOM 2.3

iMig Board meeting | ROOM 2.1

2:00pm-2:15pm COFFEE BREAK

— 2:15pm-3:45pm | **WORKSHOP 1** | ROOM 3.5

An international effort to standardize surgery for mesothelioma

Chairs: Joseph FRIEDBERG, USA; Nicolas VENISSAC, France; Veerle SURMONT, Belgium

2:15pm > 2:25pm

Lecture 1: Surgery for pleural mesothelioma - framing the issues holding us back. Joseph FRIEDBERG, USA

2:25pm > 2:40pm

Lecture 2: A proposed revision for pleural mesothelioma surgery nomenclature. Seiki HASEGAWA, Japan

2:40pm > 2:55pm

Lecture 3: A proposed synoptic operative reporting system for pleural mesothelioma surgery. Valerie RUSCH, USA

2:55pm > 3:05pm

Lecture 4: Standardizing surgical techniques and reporting for the MARS2 trial: lessons learned and opportunities for improvement. John EDWARDS, UK

3:05pm > 3:20pm

Lecture 5: Standardization of techniques, reporting, or both - what to do and how to use this information to move the field forward? Harvey PASS, USA

3:20pm > 3:35pm

Lecture 6: Completeness of resection scoring and other tools for peritoneal mesothelioma - Lessons learned from 25 years that could be applied to pleural surgery. Olivier GLEHEN, France

3:35pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

— 2:15pm-3:45pm | **WORKSHOP 2** | ROOM 2.3

Focussing on patients experience: improving mesothelioma patients and relatives management

Chairs: Dan STERMAN, USA; Linda REINSTEIN, USA (ADAO); Robert RINTOUL, UK; Philippe ASTOUL, France

2:15pm > 2:30pm

Lecture 1: Investigating suspected mesothelioma in the frail patient. Nick MASKELL, UK

2:30pm > 2:45pm

Lecture 2: Optimal management of pleural effusion and trapped lung. Gary LEE, Australia

2:45pm > 2:55pm

CO-044. Real-world toxicity with dual immunotherapy for malignant pleural mesothelioma. Barbara PUTMAN, Belgium

2:55pm > 3:05pm

CO-055. The effect of mesothelioma on the mental health of patients and carers in the UK: a cross sectional survey.

Virginia SHERBORNE, UK

3:05pm > 3:15pm

CO-054. The asbestos-induced immune microenvironment plays a key role in malignant mesothelioma pathogenesis and may be exploited for chemoprevention. Yuwaraj KADARIYA, USA

3:15pm > 3:25pm

CO-053. Natural history and cancer screening of mesothelioma patients and family members with germline mutations in BRCA1-Associated Protein-1 (BAP1) gene. Azam GHAFOR, USA

3:25pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

— 2:15pm-3:45pm | **WORKSHOP 3** | AMPHITHEATER GRAND THÉÂTRE

Imaging (AI, diagnosis, staging...)

Chairs: Sam ARMATO, USA; Isabelle OPITZ, Switzerland & Kristiaan NACKAERTS, Belgium

2:15pm > 2:30pm

Lecture 1: Best practices for clinical imaging in mesothelioma. Sharyn KATZ, USA

2:30pm > 2:45pm

Lecture 2: Preoperative planning: how imaging can support today? Thomas FRAUENFELDER, Switzerland

2:45pm > 2:55pm

CO-026. Quantitative 'T' category using MR in malignant pleural mesothelioma. Ritu GILL, USA

2:55pm > 3:05pm

CO-027. Anatomical and symptom changes in malignant pleural effusion using 4-dimensional magnetic resonance imaging. Geeshath JAYASEKERA, UK

3:05pm > 3:15pm

CO-028. Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced unresectable malignant pleural mesothelioma. Annamaria CATINO, Italy

3:15pm > 3:30pm

Lecture 3: Establishment of a modified RECIST score for peritoneal metastases: peritoneal mesothelioma as a model. Pascal ROUSSET, France

3:30pm > 3:40pm

CO-030. Development of an automated machine learning tool for reporting of MRI-Early Contrast Enhancement in Mesothelioma. Kevin BLYTH, UK

3:40pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

3:45pm-4:30pm BREAK, POSTER VIEWING & BOOTH VISIT



— 4:30pm-6:00pm | **WORKSHOP 4** | ROOM 3.5

From european mesothelioma experience to european collaborative projects initiative (iMig/ETOP joint symposium)

Chairs: Paul BAAS, The Netherlands; Ken O'BYRNE, Australia; Solange PETERS, Switzerland; Rolf STAHEL, Switzerland

4:30pm > 4:45pm

Lecture 1: From PROMISE-Meso to BEAT-Meso: the ETOP mesothelioma trials experience. Sanjay POPAT, UK

4:45pm > 5:00pm

Lecture 2: The ETOP MESOSCAPE project: translational studies data and ongoing projects. Alessandra CURIONI-FONTECEDRO

5:00pm > 5:10pm

Lecture 3: UK research project (MIST) as a model for international initiative in mesothelioma. Dean FENNEL, UK

5:10pm > 5:20pm

Late-breaking abstract. Results of the ATOMIC-MESO phase 3 trial. Peter SZLOSAREK, UK

5:20pm > 5:30pm

Late-breaking abstract.

5:30pm > 5:40pm

CO-006. Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma. Aaron S. MANSFIELD, USA

5:40pm > 5:50pm

CO-057. Low miR-155, -29c, -132 or -100 predicts longer survival with bevacizumab plus chemotherapy in patients with pleural mesothelioma from MAPS trial. Gérard ZALCMAN, France

5:50pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



— 4:30pm-6:00pm | **WORKSHOP 5** | AMPHITHEATER GRAND THÉÂTRE

Pathology advances and assessment of the tumor microenvironment

Chairs: Fabien FOREST, France; Lucian R. CHIRIEAC, USA; Richard ATTANOOS, UK

4:30pm > 4:45pm

Lecture 1: State of the art of biomarkers for immunotherapy in mesothelioma. Sanja DACIC, USA

4:45pm > 5:00pm

Lecture 2: Separating benign from malignant lesions. Luka BRCIC, Austria

5:00pm > 5:10pm

CO-001. Prospective validation of a gene expression approach for the cytological diagnosis of epithelioid, biphasic mesothelioma and mesothelial hyperplasia. Rossella BRUNO, Italy

5:10pm > 5:20pm

CO-029. A multicenter prospective feasibility study for definite diagnosis of malignant pleural mesothelioma by pleural effusion cytopathology. Masaki HASHIMOTO, Japan

5:20pm > 5:30pm

CO-020. Towards New clinicopathologic entities of peritoneal and pleural neoplasms with specific gene fusions. Nazim BENZERDJE, France

5:30pm > 5:45pm

Lecture 3: Future directions and new tools in the diagnosis of mesothelioma (AI, RNA Seq...). Sylvie LANTUEJOL, France

5:45pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

— 4:30pm-6:00pm | **WORKSHOP 6** | ROOM 2.3

Mesothelioma pre-clinical models and results

Chairs: Christophe BLANQUART, France; Kevin BLYTH, UK

4:30pm > 4:45pm

Lecture 1: PDX mesothelioma models. Marc DE PERROT, Canada

4:45pm > 5:00pm

Lecture 2: Mesothelioma explants/organoids. Marion MACFARLANE, UK

5:00pm > 5:10pm

CO-052. Derivation and characterisation of pleural mesothelioma organoid models. Robert RINTOUL, UK

5:10pm > 5:20pm

CO-016. Mapping the measured metabolome to the aberrant genomic landscape of mesothelioma in patient-derived cell lines and tumours. Michael OLANIPEKUN, UK

5:20pm > 5:30pm

CO-045. Pharmacogenomics characterization of a large collection of primary cell lines identifies novel therapeutic options for pleural mesothelioma. Jean Baptiste ASSIÉ, France

5:30pm > 5:40pm

CO-049. Development of new virus-like particles derived from the M13 bacteriophage for the specific transfer of cDNA in mesothelin-expressing cells. Tina BRIOLAY, France

5:40pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

— 6:00pm-6:30pm | **POSTER MIXER & POSTER DISCUSSION SESSION**
LE SQUARE AREA

Sponsored by



Tuesday, June 27, 2023

7:30am-8:00am DELEGATES ARRIVAL

— 8:00am-9:30am | **PLENARY 3** | AMPHITHEATER GRAND THÉÂTRE

Surgery, Radiotherapy, (neo)adjuvant therapies: what is the best combo for multimodal treatment?

Chairs: Thierry BERGHMANS, Belgium; Françoise LE PIMPEC BARTHES, France; Marc DE PERROT, Canada

8:00am > 8:15am

Lecture 1: State of surgery for pleural mesothelioma in 2023: from prospective trials to the future. Isabelle OPITZ, Switzerland

8:15am > 8:30am

Lecture 2: Optimal integration of radiotherapy with surgery. Dirk DE RUYSSCHER, The Netherlands

8:30am > 8:45am

Lecture 3: State of the art and future direction of adjuvant therapies - preoperative, intraoperative, postoperative. Patrick FORDE, USA

8:45am > 8:55am

Lecture 4: Intrapleural CAR T therapies: a new basis for multimodal treatment? Marjorie ZAUDERER, USA

8:55am > 9:05am

CO-004. Immune response to sub-ablative radiation before extended pleurectomy-decortication in pleural mesothelioma – results from the SMARTER trial. Marc DE PERROT, Canada

9:05am > 9:15am

Late-breaking abstract. First results of the EORTC 1205 phase 2 trial. Jo RASKIN, Belgium

9:15am > 9:30am | Overall Q&A or general discussion moderated by the session chairs

9:30am-10:15am BREAK, POSTER VIEWING & BOOTH VISIT

— 10:15am-11:45pm | **YOUNG INVESTIGATORS 2023** | AMPHITHEATER GRAND THÉÂTRE

Lessons and advice from previous iMig YI awardees and promising directions for mesothelioma research.

Chairs: Bruce ROBINSON, Australia; Najib RAHMAN, UK; Fabrice BARLESI, France

10:15am > 10:30am

Lecture 1: From previous iMig YI awardee. Anna NOWAK, Australia

10:30am > 10:45am

Lecture 2: From previous iMig YI awardee: non-invasive biomarkers (VOCs...) for mesothelioma. Kevin LAMOTE, Belgium

10:45am > 10:55 am

CO-015. Unveiling intra-tumor heterogeneity and evolutionary processes in malignant pleural mesothelioma at the single cell level. Matthieu FOLL, France

10:55am > 11:05am

CO-003. Deciphering dysfunctional heterogeneity of tumor-infiltrating lymphocytes from malignant pleural mesothelioma. Katarzyna TOMCZAK, USA

11:05am > 11:15am

CO-022. Improving the response of mesothelioma to immunotherapy with targeted epigenetic editing. Kofi STEVENS, Australia

11:15am > 11:25am

CO-041. Adjuvant dendritic cell-based immunotherapy after surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Michelle V. DIETZ, The Netherlands

11:25am > 11:45am | Overall Q&A or general discussion moderated by the session chairs

11:45am-12:00pm LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES

— 12:00pm-1:00pm | **INDUSTRIAL SYMPOSIUM - RS ONCOLOGY** | AMPHITHEATER GRAND THÉÂTRE


New Horizons for Cancer Therapy - Targeting Oxidative Stress Vulnerabilities

(Luncheon break in the room)

Opening Remarks. Jarrett Duncan, Esq. CEO, RS Oncology

Scientific Discovery. Brian Cunniff, PhD, Chief Science Officer, University of Vermont

Case Study: MITOPE Clinical Trial. Sean Dooloo, MD, Consultant, University of Leicester



1:00pm-1:15pm COFFEE BREAK

— 1:15pm-2:45pm | **WORKSHOP 7** | AMPHITHEATER GRAND THÉÂTRE

Immunotherapies: new drugs, strategies including cell therapies, and trials

Chairs: Joachim AERTS, The Netherlands; Hedy KINDLER, USA; Takashi NAKANO, Japan

1:15pm > 1:30pm

Lecture 1: CAR-T therapy from basic side and how to make them better, different targets. Astero KLAMPATSA, UK

1:30pm > 1:45pm

Lecture 2: CAR T and T cell receptor constructs (TruC) for mesothelioma - ready for prime time? Raffit HASSAN, USA

1:45pm > 1:55pm

CO-007. Chemotherapy enhances LAG-3 expressing progenitor exhausted CD8+ T cells in murine mesothelioma that can be targeted by immune checkpoint blockade. Jonathan CHEE, Australia

1:55pm > 2:05pm

CO-008. PD-L1 checkpoint blockade promotes regulatory T-cell activity which underlies therapy resistance in mesothelioma. Mandy VAN GULIJK, The Netherlands

2:05pm > 2:15pm

CO-014. Quantitative cell dynamics of macrophage-directed cytotoxicity in mesothelioma. Malik HAMAIDIA, Belgium

2:15pm > 2:30pm

Lecture 3: A review of other current and future immunotherapy strategies. Jonathan CHEE, Australia

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

— 1:15pm-2:45pm | **WORKSHOP 8** | ROOM 3.5

iMig/patient associations track: asbestos control, health promotion, advocacy, prevention and patients experience (MARF/iMig)

Chairs: Julie POWERS, USA; Harlinde DE SCHUTTER, Belgium; Jacques FAUGERON, France

1:15pm > 1:30pm

Lecture 1: A patient, family and country point of view of mesothelioma experience. Eric JONCKHEERE, Belgium

1:30pm > 1:45pm

Lecture 2: MARF experience in health promotion, advocacy and prevention. Julie POWERS, USA

1:45pm > 1:55pm

Lecture 3: Asbestos in India: news from the ground. Muralidhar VENKITESWARAN and Pankaja RAGHAV, India

1:55pm > 2:10pm

CO-034. Italian pool of asbestos workers cohorts: a mortality study. Daniela FERRANTE, Italy

2:10pm > 2:20pm

CO-032. Burden of malignant mesothelioma in China during 1990-2019 and projections to 2029. Tianhui CHEN, China

2:20pm > 2:30pm

CO-036. Failure of annual low-dose CT scanning to detect early malignant mesothelioma in an occupational cohort. Steven B. MARKOWITZ, USA

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

— 1:15pm-2:45pm | **WORKSHOP 9** | ROOM 2.3

Peritoneal mesothelioma

Chairs: Marcello DERACO, Italy; Olivier GLEHEN, France; Paul SUGARBAKER, USA

1:15pm > 1:30pm

Lecture 1: HIPEC, EPIC and NIPEC for peritoneal mesothelioma, what is the best cocktail? Paul SUGARBAKER, USA

1:30pm > 1:45pm

Lecture 2: PIPAC and PITAC to treat mesothelioma: where are we and where do we go? Olivia SGARBURA, France

1:45pm > 1:55pm

CO-033. Clinicopathologic characteristics and clinical outcomes of patients with testicular mesotheliomas.

Michael OFFIN, USA

1:55pm > 2:05pm

CO-040. Ten years of french multicentric experience in the management of diffuse malignant peritoneal mesothelioma with 924 patients. Barbara NOIRET, France

2:05pm > 2:15pm

CO-039. The UK and Ireland national multi-disciplinary team meeting for peritoneal mesothelioma: optimising outcomes through better selection for surgery. Victor KUNG, UK

2:15pm > 2:30pm

Lecture 3: The UK peritoneal multi-disciplinary team - establishing a national approach. Tom CECIL, UK

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

2:45pm-3:30pm BREAK, POSTER VIEWING & BOOTH VISIT



— 3:30pm-5:00pm | **WORKSHOP 10** | AMPHITHEATER GRAND THÉÂTRE

Mesothelioma biology and novel targets: from bench to bedside.

Chairs: Dean FENNELL, UK; Luc WILLEMS, Belgium; Steven M. ALBELDA, USA

3:30pm > 3:45pm

Lecture 1: Induction of type 1 interferon in mesothelioma. Emanuela FELLEY BOSCO, Switzerland

3:45pm > 4:00pm

Lecture 2: Targeting PRX3 as a therapeutic approach for mesothelioma. Brian CUNNIFF, USA

4:00pm > 4:10pm

CO-013. Exosome-based MiRNA delivery for malignant mesothelioma treatment. Marco TOMASETTI, Italy

4:10pm > 4:20pm

CO-025. Prognostic significance of EMT gene signature in mesothelioma. Licun WU, Canada

4:20pm > 4:30pm

CO-012. In vitro, preclinical and patients' data evidence for a role of eosinophils in mesothelioma response to chemotherapy. Mégane WILLEMS, Belgium

4:30pm > 4:40pm

CO-046. PEMbrolizumab plus lenvatinib in second and third line pleural mesothelioma patients: a single arm phase II study (PEMMELA). Li-Anne H. DOUMA, The Netherlands

4:40pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

— 3:30pm-5:00pm | **WORKSHOP 11** | ROOM 3.5

iMig/patient associations track: focus on the patient experience: supportive care...

Chairs: Federica GROSSO, Italy; Laurent GREILLIER, France; Loic LANG-LAZDUNSKI, Switzerland

3:30pm > 3:45pm

Lecture 1: Managing pain in mesothelioma. Pascale TOMASINI, France

3:45pm > 4:00pm

Lecture 2: What is the optimal follow-up for mesothelioma patients not having active tumor treatment? Anna BIBBY, UK

4:00pm > 4:10pm

CO-050. Exploring the experiences and coping strategies of individuals, below the age of 60, living with mesothelioma.

Benjamin LOND, UK

4:10pm > 4:20pm

CO-031. Establishing the mesothelioma UK research centre: co-production with patients and families.

Bethany TAYLOR, UK

4:20pm > 4:30pm

CO-048. Fatigue is associated with adverse health-related quality of life and survival in malignant pleural mesothelioma.

Mohamed RAHOUMA, USA

4:30pm > 4:40pm

CO-051. Cough and mesothelioma (CAM): emerging themes from a qualitative study exploring the impact of cough on quality of life. Kate SLAVEN, UK

4:40pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

— 3:30pm-5:00pm | **WORKSHOP 12** | ROOM 2.3

Biomarkers, Genetics/Bioinformatics

Chairs: Michele CARBONE, USA; Didier JEAN, France

3:30pm > 3:45pm

Lecture 1: Molecular axes and specialized tumor profiles driving inter-tumor heterogeneity in mesothelioma. Lynnette FERNANDEZ-CUESTA, France

3:45pm > 4:00pm

CO-047: HMGB1 serves as the key factor in the development of mesothelioma caused by both asbestos exposure and BAP1 mutations. Haining YANG, USA

4:00pm > 4:10pm

CO-010. The MexTAq collaborative cross: host genetics affects disease latency, but has little influence once established disease. Scott Andrew FISHER, Australia

4:10pm > 4:20pm

CO-005. Exploration of heterogeneity in pleural mesothelioma primary cell lines and associated tumors at the single cell level. Maya ARNOULD, France

4:20pm > 4:30pm

CO-023. Spatial and temporal genomic heterogeneity of mesothelioma. Venkateswar ADDALA, Australia

4:30pm > 4:45pm

CO-019. Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: the baseline measurement. Kathleen ZWIJSEN, Belgium

4:45pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

— 5:00pm-5:30pm | **POSTER MIXER & POSTER DISCUSSION SESSION**
LE SQUARE AREA

Sponsored by



FROM 7:00pm | **iMig GALA DINNER - LILLE ART MUSEUM (Palais des Beaux-Arts) including iMig medals & awards announcement.**

Wednesday, June 28, 2023

8:00am-8:30am DELEGATES ARRIVAL

— 8:30am-10:00am | **PLENARY 4** | AMPHITHEATER GRAND THÉÂTRE

Not all patients die of Mesothelioma?! Exceptional survivals / cure results / perspectives

Chairs: Anne TSAO, USA; Jeremy STEELE, UK; Laurent VILLENEUVE, France

8:30am > 8:45am

Lecture 1: NCI surgical clinical trial for mesothelioma developing in carriers of germline BAP1 mutations and their affected relatives: unique clinical characteristics of these patients. David SCHRUMP, USA

8:45am > 9:00am

Lecture 2: BAP1 is a novel regulator of HIF-1 α : clinical implications. Michele CARBONE, USA

9:00am > 9:10am

CO-056. Final analysis of JME-001: a phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant. Nobukazu FUJIMOTO, Japan

9:10am > 9:20am

Late-breaking abstract. IND 227 - IFCT 1901 phase 3 - trial first results. Arnaud SCHERPEREEL, France

9:20am > 9:30am

CO-009. Real-life efficacy of nivolumab plus ipilimumab in untreated, unresectable malignant pleural mesotheliomas: results of french early access program. Laurent GREILLIER, France

9:30am > 9:45am

Lecture 3: Is it possible to be cured from a peritoneal mesothelioma? Clarisse EVENO, France

9:45am > 10:00am | Overall Q&A or general discussion moderated by the session chairs

10:00am-10:30am BREAK, POSTER VIEWING & BOOTH VISIT



— 10:30am-12:00pm | **WORKSHOP 13** | ROOM 3.5

Initial localized disease, oligoprogression: ready for changes in treatment paradigm?

Chairs: Julien MAZIÈRES, France; Sjaak BURGERS, the Netherlands; Andreas RIMNER, USA

10:30am > 10:45am

Lecture 1: What is oligoprogression in pleural mesothelioma and how should we manage it? Crispin HILEY, UK

10:45am > 11:00am

Lecture 2: Proton therapy for localized disease. Charles SIMONE, USA

11:00am > 11:10am

CO-021. Less could be more – patients with over 3-year median survival show no significant difference between radical surgery and a less invasive approach. Warren NASELSKY, USA

11:10am > 11:20am

CO-017. Recurrence patterns after pleurectomy decortication for pleural mesothelioma (PM). Juuso PAAJANEN, USA

11:20am > 11:30am

CO-002. Clinical outcomes of stereotactic body radiotherapy for mesothelioma. Jacob Y. SHIN, USA

11:30am > 11:50am

Pro/Con discussion of the value of oligodisease strategies in the IO era, using clinical cases. Andreas RIMNER, USA and Giovanni CERESOLI, Italy

11:50am > 12:00pm | Overall Q&A or general discussion moderated by the session chairs

— 10:30am-12:00pm | **WORKSHOP 14** | ROOM 2.3

Nurses and allied health: advances in mesothelioma patients care

Chairs: Liz DARLISON, UK; Melissa CULLIGAN, USA; Thierry PIETERS, Belgium

10:30am > 10:45am

Lecture 1: Integrating palliative care Across the mesothelioma patient journey. Sarah HARGREAVES and Bethany TAYLOR, UK

10:45am > 11:00am

Lecture 2: Equitable access to clinical trials - from a national approach to international suggestions. Leah TAYLOR, UK

11:00am > 11:10am

Lecture 3: Broadening the scope of practice for mesothelioma nurses - establishing a nurse-led pleural service. Jennifer LATHAM, UK

11:10am > 11:20am

CO-035. Integrating a patient organisation for rare thoracic tumours (TUTOR) in the network of advocates for mesothelioma patients and caregivers in Italy. Susanna LETO DI PRIOLO, Italy

11:20am > 11:30am

CO-037. How can mesothelioma clinical nurse specialists optimise clinical decision making for mesothelioma patients? Zoe DAVEY, UK

11:30am > 11:40am

CO-038. Quality-of-Life and dyspnea experience before and after lung-sparing surgery for pleural mesothelioma: a scoping review using the theory of unpleasant. Melissa CULLIGAN, USA

11:40am > 12:00pm Overall Q&A or general discussion moderated by the session chairs

— 10:30am-12:00pm | **WORKSHOP 15** | AMPHITHEATER GRAND THÉÂTRE

Sponsored by



Is personalized medicine ready for prime time in mesothelioma?

Chairs: Gérard ZALCMAN, France; Dean FENNELL, UK or Marjorie ZAUDERER, USA

10:30am > 10:45am

Lecture 1: MTAP, NF2/YAP/TAZ/Hippo agents, and VISTA target in mesothelioma. Ibiayi DAGOGO-JACK, USA

10:45am > 11:00am

Lecture 2: New biological targets for mesothelioma. Yoshitaka SEKIDO, Japan

11:00am > 11:10am

CO-042. A gut microbiota rheostat forecasts response to PDL1-VEGF blockade in mesothelioma. Aleksandra BZURA, UK

11:10am > 11:20am

CO-018. Diversity of tumor immune microenvironment landscape of epithelioid malignant pleural mesothelioma in patients with primary surgically resected tumors. Katarzyna TOMCZAK, USA

11:20am > 11:30am

CO-011. The immune response to mesothelioma is directed at a highly restricted set of tumour antigens. Jessica BOULTER, Australia

11:30am > 11:45am

Lecture 3: An overview of the best candidate drugs and strategies for personalized medicine in mesothelioma. Anne TSAO, USA

11:45am > 12:00pm | Overall Q&A or general discussion moderated by the session chairs

12:00pm-12:45pm LUNCHEON BREAK - DISTRIBUTION OF FREE LUNCHBOXES FOR ALL THE DELEGATES





DLD
DIAGNOSTIKA GMBH

DLD Gesellschaft für Diagnostika
und medizinische Geräte mbH
Adlerhorst 15 · 22459 Hamburg · Germany
Phone +49-40-555 871 0
contact@dld-diagnostika.de
www.dld-diagnostika.de

Product Information

Calretinin ELISA

- Catalog-No.** EA611/96
Enzyme immunoassay for the quantitative determination of human calretinin in plasma and serum
- Format** Microtiter plate (12 x 8 determinations, single break apart wells, coated with polyclonal calretinin antibodies)
- Procedure**
Sample volume: 15 µl patient serum or plasma
Sample Preparation: 60 min incubation at room temperature
ELISA: 4.5 hours total incubation time at room temperature
Measurement in ELISA reader at 450 nm (620 nm reference)
6 Standards with range: 0.25 ng/ml – 4.0 ng/ml
2 Kit controls, lyophilized
Enzyme Conjugate 200x concentrated
Wash buffer 50x concentrated
All other reagents ready for use
- Clinical Fields** Oncology, cancer screening, occupational diseases
- Diseases** Mesothelioma
- Sensitivity** 0.05 ng/ml
- Characteristics**
Sandwich ELISA with microtiter plate format
Highly specific and sensitive rabbit anti-calretinin antibody
Good linearity between 0.47 ng/ml – 3.03 ng/ml
Easy to handle, total assay time is 6 hours
Suitable for testing large series of serum or plasma samples
Validated in larger case-control studies
Involved in prospective studies
Involved in EVA-Mesothel pilot study
CE-marked IVD

— 12:45pm-2:15pm | **PLENARY 5** | AMPHITHEATER GRAND THÉÂTRE

Joint iMig/IASLC session: work in progress and what's next in mesothelioma field?

Chairs: Paul BAAS, The Netherlands; Paul VAN SCHIL, Belgium; Raphael BUENO, USA

12:45pm > 1:00pm

iMig AWARDS AND YOUNG INVESTIGATORS AWARDS

1:00pm > 1:10pm

Lecture 1: Joint IASLC/iMig initiatives in pleural mesothelioma field.

Paul VAN SCHIL, Belgium and Arnaud SCHERPEREEL, France

1:10pm > 1:25pm

Lecture 2: Promises and pitfalls of AI for mesothelioma imaging? Sam ARMATO, USA

1:25pm > 2:05pm

Lecture 3: Interactive panel discussion ("MTB") about optimized management and future directions in pleural mesothelioma management starting from clinical cases.

Bruce ROBINSON, Australia; Isabelle OPITZ, Switzerland; Dean FENNELL, UK; Aaron MANSFIELD, Anne TSAO, USA; Andreas RIMNER, USA; Melissa CULLIGAN, USA & Ken O'BYRNE, Australia

2:05pm > 2:15pm | Overall Q&A or general discussion moderated by the session chairs

2:15pm-2:30pm | **PRESIDENTIAL CLOSING & SAVE THE DATE iMig 2025**

Arnaud SCHERPEREEL and Virginie WESTEEL, France; iMig 2025 chair



Leigh Day Lawyers have specialised in asbestos cases for over 30 years, both in the UK and across the globe.

Our firm's legal cases have set precedents which other law firms follow. We stand out amongst our contemporaries. Three examples of our legal cases are below:

- **Dr Rudd v John Bridle**

We represented Dr Robin Rudd, a leading medical expert in his successful court case against John Bridle, an asbestos lobbyist who claims chrysotile products are safe. Bridle asserted Dr Rudd was preparing court reports stating chrysotile was dangerous simply for profit.

- **Bains & Others v Moore & K2 Intelligence**

We represented one of our partners, Harminder Bains, and numerous well-known anti-asbestos campaigners who had been spied on Rob Moore. He was a spy hired by the K2 Intelligence Agency. The court case revealed the Kazakhstan asbestos industry had hired K2 to find out information about anti-asbestos campaigners.

- **Dring v Cape**

We represented the Asbestos Victims Support Groups Forum, a leading UK charity, in their legal case against Cape, an international firm who manufactured asbestos products. The charity succeeded in obtaining vital historical documents from Cape which Cape intended to destroy as they revealed the "real" extent of the dangers of asbestos.

We are now assisting the charity who are demanding that Cape provides £10 million for medical research for finding a cure for mesothelioma.



Highly respected industrial disease practice offering first-rate representation to claimants suffering asbestos-related diseases. Features prominently in headline disease cases and retains strong links to support groups and non-profits catering for those with mesothelioma.

International Legal Directory
Chambers and Partners

Please visit our stand.
We look forward to seeing you.

Website: www.leighday.co.uk/asbestos

Email: asbestos@leighday.co.uk

Twitter: @LD_Asbestos

Leigh Day

Selected posters

Monday, June 26, 2023

(posters will be available for consultation throughout the day in the poster area)

TRACK 1: BIOMARKERS, GENETICS/BIOINFORMATICS

PO-012

CHEK1 and BAP1 combination as a potential prognostic biomarker for pleural mesothelioma.

Vasiliki Panou (Odense, Denmark), Weronika Maria Szejniuk (Aalborg, Denmark), Christos Meristoudis (Aalborg, Denmark), Azadeh Asghari Birbaneh (Hjørring, Denmark), Oluf Dimitri Røe (Levanger, Norway)

PO-013

Prognostic impact of inflammation in malignant pleural mesothelioma: large-scale analysis of a single center cohort.

Ludovic Fournel, Thomas Charrier, Maxime Huriet, Diane Damotte, Marco Alifano (Paris, France)

PO-024

Transcriptomic profiling identifies a 6-gene mesothelioma-specific prognostic gene signature that predicts survival.

Scott A. Fisher, Kiarash Behrouzfar, Kimberley Patrick, Steve E. Mutsaers, Grant Morahan, Richard A. Lake (Perth, Australia)

PO-031

VEGFR2 /CD34 expression associated with longer survival in patients with malignant pleural mesothelioma (MPM) in the IFCT-GFPC-0701 MAPS phase 3 trial.

Levallet Guénaëlle (Caen, France), Dubois Fatéméh (Caen, France), Elie Nicolas (Caen, France), Creveuil Christian (Caen, France), Brosseau Solenn (Paris, France), Danel Claire (Paris, France), Scherpereel Arnaud (Lille, France), Lantuejoul Sylvie (Lyon, France), Mazières Julien (Toulouse, France), Greillier Laurent (Marseille, France), Audigier-Valette Clarisse (Toulon, France), Bergot Emmanuel (Caen, France), Moro-Sibilot Denis (Grenoble, France), Molinier Olivier (Le Mans, France), Léna Hervé (Rennes, France), Monnet Isabelle (Créteil, France), Morin Franck (Paris, France), Gounant Valérie (Paris, France), Zalcmán Gérard (Paris, France)

PO-034

In silico analysis enabled the identification of new putative markers for MPM.

Luisa Bisceglia (Pisa, Italy), Federica Morani (Pisa, Italy), Lara Guerrieri (Pisa, Italy), Pinar Çakilkaya (Copenhagen, Denmark), Eric Santoni-Rugiu (Copenhagen, Denmark), Lars H. Engelholm (Copenhagen, Denmark), Niels Behrendt (Copenhagen, Denmark), Federica Gemignani (Pisa, Italy), Stefano Landi (Pisa, Italy)

PO-042

Inherited Predisposition to Mesothelioma: BAP1 Syndrome and other HRR Defects.

Marika Sculco (Novara, Italy), Marta La Vecchia (Novara, Italy), Anna Aspesi (Novara, Italy), Michela Giulia Clavenna (Novara, Italy), Michela Salvo (Novara, Italy), Giulia Borzonovi (Novara, Italy), Alessandra Pittaro (Turin, Italy), Gianluca Witel (Turin, Italy), Francesca Napoli (Turin, Italy), Angela Listi (Turin, Italy), Elisabetta Casalone (Turin, Italy), Federica Grosso (Alessandria, Italy), Giulio Rossi (Brescia, Italy), Ottavio Rena (Novara, Italy), Renzo Baldorini (Novara, Italy), Daniela Giachino (Turin, Italy), Paolo Bironzo (Turin, Italy), Antonella Maffè (Cuneo, Italy), Greta Ali (Pisa, Italy), Lisa Elefanti (Padua, Italy), Chiara Menin (Padua, Italy), Luisella Righi (Turin, Italy), Cristian Tampieri (Turin, Italy), Giorgio Vittorio Scagliotti (Turin, Italy), Daniela Ferrante

(Novara, Italy), Manuela Gangemi (Turin, Italy), Enrica Migliore (Turin, Italy), Corrado Magnani (Novara, Italy), Giuseppe Matullo (Turin, Italy), Irma Dianzani (Novara, Italy)

PO-049

Developing a community-driven knowledge base molecular pathway for malignant pleural mesothelioma.

Marvin Martens (Maastricht, The Netherlands), Franziska Kreidl (Maastricht, The Netherlands), Friederike Ehrhart (Maastricht, The Netherlands), Didier Jean (Paris, France), Merlin Mei (NC, USA), Holly Mortensen (NC, USA), Alistair Nash (Australia), Penny Nymark (Stockholm, Sweden), Lydie Lane (Geneva, Switzerland), Chris Evelo (Maastricht, The Netherlands), Ferdinando Cerciello (Bern, Switzerland)

PO-053

Effusion cytokine profile as a biomarker of BAP1 loss in pleural mesothelioma.

Alistair Nash (Perth, Australia), Ebony Rouse (Perth, Australia), Tina Firth (Perth, Australia), Gary Lee (Perth, Australia), Alec Redwood (Perth, Australia), Bruce Robinson (Perth, Australia), Jenette Creaney (Perth, Australia)

PO-057

Prediction of Resistance to Chemotherapy using Somatic Copy Number Variation in Mesothelioma: Results of a multi-centre retrospective cohort study.

Kevin G Blyth (Glasgow, UK), Andrew C Kidd (Glasgow, UK), Craig Dick (Glasgow, UK), Gordon W Cowell (Glasgow, UK), Colin Noble (Glasgow, UK), Alan Winter (Glasgow, UK), Laura Miller (Glasgow, UK), Paul Westwood (Glasgow, UK), Rachael Ellis (Glasgow, UK), David Stobo (Glasgow, UK), Yun Yu Chen (Edinburgh, UK), Loan Somarriba (Edinburgh, UK), H Hall (Glasgow, UK), A Bloom (Glasgow, UK), C Miller (Glasgow, UK), J Roche (Glasgow, UK), D Lewis (Glasgow, UK), W Sloan (Glasgow, UK), C Poile (Leicester, UK), S Meakins (Cambridge, UK), M Evison (Manchester, UK), R Rintoul (Cambridge, UK), D Fennell (Leicester, UK)

PO-058

Transcriptomic Characterization of Extracellular Vesicles Secreted By Pleural Mesothelioma Reveals a Clinically Relevant Gene Signature.

Agnieszka Kraft, Mayura Meerang, Michaela B Kirschner, Valentina Boeva, Isabelle Opitz (Zurich, Switzerland)

PO-059

Genome-wide DNA methylation analysis reveals the existence of many differentially methylated CpG sites with biomarker potential in the MPM epigenome.

Vandenhoeck Janah Edegem, De Meulenaere Nele Edegem, Ibrahim Joe Edegem, Peeters Dieter Edegem, Van Schil Paul Edegem, Hendriks Jeroen Edegem, Raskin Jo Edegem, Meerbeeck Jan Edegem, Van Camp Guy Edegem, Op de Beeck Ken Edegem (Belgium)

PO-066

Exhaled breath analysis predicts treatment response in malignant pleural mesothelioma patients.

Ellen Heirwegh (Antwerp, Belgium), Eline Schillebeeckx (Antwerp, Belgium), Eline Janssens (Antwerp, Belgium), Veerle Surmont (Ghent, Belgium), Kristiaan Nackaerts (Leuven, Belgium), Ely Marcq (Antwerp, Belgium), Jan P. van Meerbeeck (Antwerp, Belgium), Kevin Lamote (Antwerp, Belgium)

PO-068

Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients Treated with Intracavitary Cisplatin-Fibrin.

Mayura Meerang, Jan Mengers, Martina Haberecker, Michaela Kirschner, Nadine Bosbach, Olivia Lauk, Isabelle Opitz, (Zurich, Switzerland)

PO-071

Monitoring Serum CA-125 and Mesothelin Levels After Pleurectomy Decortication in Pleural Mesothelioma.

Ahmed Sadek, Juuso Paajanen, William G. Richards, Emanuele Mazzola, Yue Xie, Kristina Sidopoulos, John Kuckelman, Ritu R. Gill, Raphael Bueno (Boston, USA)

PO-082

A serum biomarkers panel evaluation revealed a potential diagnostic role for IL-6, HGF, E-SELECTIN, and OPN in malignant pleural mesothelioma.

Roberto Silvestri, Filomena Rea, Margherita Piccardi, Martina Lari, Vittorio Aprile, Diana Bacchin, Alessandra Lenzini, Stylianos Korasidis, Gaetana Gambino, Riccardo Marino, Marco Napoletano, Leonardo Rossi, Rudy Foddìs, Marco Lucchi, Roberto Giovannoni, Stefano Landi, Federica Gemignani (Pisa, Italy)

PO-083

Diverging expression of CHEK 1 in Malignant Mesothelioma treated with radiotherapy: A Case Report.

Asghari Birbaneh (Hjoerring, Denmark), Meristoudis Christos (Aalborg, Denmark), Panou Vasiliki (Odense, Denmark), Røe Oluf Dimitri (Aalborg, Denmark)

PO-087

The role of PD-L1 expression as a prognostic factor of overall survival of patients with malignant pleural mesothelioma.

Tatyana Barbolina, Kozlov Nikolay Aleksandrovich, Lubchenko Lyudmila Nikolaevna, Rotobelskaya Lidiya Evgenievna, Bagrova Svetlana Gennadiyevna, Laktionov Konstantin Konstantinovich, Bychkov Mark Borisovich (Moscow, Russia)

PO-088

Primary cilium BBSome gene expression profile during the exposure of benign mesothelial cells to pleural effusion fluid of different etiologies in 3D.

Rajesh Jagirdar, Eleana Pitaraki, Erasmia Rouka, Sotirios G Zarogiannis, Chrissy Hatzoglou, Konstantinos I Gourgouliannis (Larissa city, Greece)

PO-091

New immunohistochemical markers for pleural mesothelioma subtyping.

Iosè Di Stefano, Greta Ali, Anello Marcello Poma, Rossella Bruno, Carmelina Cristina Zirafa, Franca Melfi, Gabriella Fontanini (Pisa, Italy)

PO-093

MACADAM (Mesothelioma Clinical Data platform), an advanced clinical data platform for mesothelioma investigation and improvement of clinical pathways.

Luigi Cerbone, Giulia Cuniatti, Sara Delfanti, Antonina Maria De Angelis, Angela Cimorelli, Francesco Boccuzzi, Dario Ricci Alessandria, Federica Grosso (Alessandria, Italy)

PO-094

Type 3 collagen, a potential new marker for the differential diagnosis of malignant pleural mesothelioma associated with overall patient survival.

Christophe Blanquart (Nantes, France), Christine Sagan (Nantes, France), Sophie Deshayes (Nantes, France), Judith Fresquet (Nantes, France), Didier Jean (Paris, France), Charly Liddell (Nantes, France)

PO-095

CD27-IgD- B cells might portray an exhausted B cell phenotype resulting in lack of response to checkpoint inhibitor treatment in pleural mesothelioma.

Belderbos R.A., Marcella Willemsen, Odilia B.J. Corneth, Daphne Dumoulin, Rudi W. Hendriks, Joachim G.J.V. Aerts (Rotterdam, the Netherlands)

PO-100

BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to chemotherapy in patients with malignant pleural mesothelioma.

Muzaffer Metintas (Eskisehir, Turkey), Tunahan Yüce (Eskisehir, Turkey), Güntülü Ak (Eskisehir, Turkey), Emine Dundar (Eskisehir, Turkey), Vasiliki Panou (Eskisehir, Turkey), Oluf Dimitri Røe (Levanger, Norway), Selma Metintas (Eskisehir, Turkey)

PO-102

A Danish and a Turkish cohort of patients with pleural mesothelioma treated with first line pemetrexed-based chemotherapy: differences, similarities.

Vasiliki Panou (Odense, Denmark), Güntülü Ak (Eskisehir, Turkey), Weronika Maria Szejniuk (Aalborg, Denmark), Muzaffer Metintas (Eskisehir, Turkey), Selma Metintas (Eskisehir, Turkey), Emine Dundar (Eskisehir, Turkey), Christos Meristoudis (Aalborg, Denmark), Oluf Dimitri Røe (Aalborg, Denmark)

PO-105

A Breathomics Based Approach To Improve Mesothelioma Diagnosis.

Sam Bonsall (Sheffield, UK), Sarah Haywood-Small (Sheffield, UK), Nicholas Peake (Sheffield, UK), Mari Herigstad (Sheffield, UK), Jason Webber (Swansea, UK)

PO-109

Serial serum mesothelin (SM) as a biomarker for disease progression and mortality in pleural mesothelioma (PM).

Geraldine A Lynch (Bristol, UK), Anna Morley (Bristol, UK), William Cooper (Bristol, UK), Anthony Edey (Bristol, UK), Duneesha De Fonseka (Sheffield, UK), Jenny Symonds (Bristol, UK), Louise Staddon (Bristol, UK), Sonia Patole (Bristol, UK), Kevin G Blyth (Glasgow, UK), Nick A Maskell (Bristol, UK), Anna C Bibby (Bristol, UK)

PO-111

Defining a new diagnostic biomarker panel for malignant pleural mesothelioma using a novel proteomic technique.

Eline Schillebeeckx (Antwerp, Belgium), Esperanza Fernandez (Ghent, Belgium), An Staes (Ghent, Belgium), Jan P. van Meerbeeck (Antwerp, Belgium), Kris Gevaert (Ghent, Belgium), Kevin Lamote (Antwerp, Belgium)

PO-112

Krebs von den Lungen 6 (KL-6) is a potential pleural effusion based diagnostic biomarker in pleural mesothelioma.

Balazs Hegedüs, Hannah Baumeister, Paul Stockhammer, Francesco Bonella, Dirk Theegarten, Till Plönes, Martin Schuler, Servet Bölükbas, Clemens Aigner (Essen, Germany)

PO-117

Clinicopathologic characteristics of adolescent and young adult (AYA) patients with mesothelioma.

Owen Mitchell, Austin Wesevich, Michael Drazer, Hedy Kindler (Chicago, IL, USA)

PO-118

Circulating biomarkers in asbestos-exposed individuals and mesothelioma patients.

Licun Wu, Fatemeh Zaeimi, Zhihong Yun, Marc de Perrot (Toronto, Canada)

PO-119

Prognostic Relevance of BAP1 Gene Mutational Status in Patients with Pleural, Peritoneal, and Biventricular Mesothelioma.

Andrew Hermina, Allen C. Zhu, Jung Woo Kwon, Owen Mitchell, Hedy Kindler, Michael Drazer, Jeffrey Mueller, Aliya N. Husain (Chicago, USA)

PO-120

Primary cilium (PC) associated BBS7 gene is differentially regulated in response to osmotic stress and depending on 2D or 3D culture model.

Rajesh Jagirdar, Erasmia Rouka, Eleana Pitaraki, Chrissy Hatzoglou, Sotirios G Zarogiannis, Konstantinos Gourgouliannis (Larissa city, Greece)

PO-151

BAP1-related tumor predisposition syndrome (BAP1-TPDS) in a patient with diagnosis of choroid melanoma, peritoneal mesothelioma, and cholangiocarcinoma.

Tudini, Lanfiuti, Sidoni, Venditti, Verna, Mutti (L'Aquila, Italy)

PO-164

Proteomics markers as potential tools for Pleural Mesothelioma risk assessment.

Elton Jalis Herman (Turin, Italy), Alessandra Allione (Turin, Italy), Clara Viberti (Turin, Italy), Elisabetta Casalone (Turin, Italy), Chiara Catalano (Turin, Italy), Carla Debernardi (Turin, Italy), Marcello Manfredi (Novara, Italy), Elisabete Weiderpass (Lyon, France), Antonio Agudo (L'Hospitalet de Llobregat, Spain), Nina Kaiser (Bochum, Germany), Georg Johnen (Bochum, Germany), Irma Dianzani (Novara, Italy), Giuseppe Matullo (Turin, Italy)

TRACK 3: IMAGING (INCLUDING STAGING ISSUES, INNOVATIONS, AI...)

PO-084

Optimising radiotracer production and in vivo PET-CT protocols to track PD-L1 distribution and expression in mesothelioma.

Tracy Hoang, Shifaza Mohamed, Joseph Ioppolo, Kirsty Richardson, Heidi Esendal, Laurence Morandeau, Melvin Chin, Roslyn Francis, Anna Nowak, Alistair Cook (Perth, Australia)

PO-104

Extent of discordant therapeutic response classification in malignant pleural mesothelioma by expert readers: A multicentre retrospective cohort study.

Gordon W. Cowell, Colin Noble, David B. Stobo, Andrew C. Kidd, Selina Tsim, Kevin G. Blyth (Glasgow, UK)

PO-106

Nodal predominant pattern of failure in malignant pleural mesothelioma receiving immunotherapy.

Leonid Roshkovan, Corey Lanzer, Melina Marmarelis, Keith Cengel, Sharyn I. Katz (Philadelphia, PA, USA)

PO-110

Malignant pleural mesothelioma mimicking a complex parapneumonic effusion: a case report.

Leonid Roshkovan, Sharyn Katz (Philadelphia, PA, USA)

PO-113

Diagnostic Value and Consistency of ADC and Dynamic Contrast MR Examination in Differentiating Epithelioid and Non-Epithelioid Subtypes in Malignant Ple.

Nevin Aydin, Guntulu Ak, Selma Metintas, Muzaffer Metintas (Eskisehir, Turkey)

PO-114

Back-translation of human MRI endpoints of Mesothelioma to a Genetically Defined Mouse Model.

Geeshath Jayasekera, Pooyeh Farahmand, Claire Rooney, Gaurav Malviya, David Lewis, Daniel Murphy, Kevin G Blyth, (Glasgow, UK)

PO-138

Artificial intelligence for the segmentation of mesothelioma: analysis of performance based on computer probability outputs (CALGB 30901, Alliance).

Mena Shenouda (Chicago, IL, USA), Eyjólfur Guðmundsson (Reykjavik, Iceland), Feng Li (Chicago, IL, USA), Chris M. Straus (Chicago, IL, USA), Hedy L. Kindler (Chicago, IL, USA), Arkadiusz Z. Dudek (St. Louis Park, MN, USA), Thomas E. Stinchcombe (Durham, NC, USA), Xiaofei Wang (Durham, NC, USA), Adam Starkey (Chicago, IL, USA), Samuel G. Armato III (Chicago, IL, USA)

TRACK 4: PATIENT EXPERIENCE: SUPPORTIVE CARE, SYMPTOMS MANAGEMENT

PO-130

Facilitators of and barriers to continuity with GPs in primary palliative cancer care: A mixed-methods systematic review.

Emilie Couchman (Sheffield, UK), Steph Ejeqi-Memeh (Sheffield, UK), Sarah Mitchell (Leeds, UK), Clare Gardiner (Sheffield, UK)

PO-131

Facilitators and barriers to early diagnosis of malignant mesothelioma (FILMM): a qualitative study of patient experiences living in England, UK.

Oviasu Osaretin, Coleby Dawn, Padley Wendy, Hinsliff-Smith Kathryn (Leicester, UK)

PO-132

Mental health and well-being living with mesothelioma - impacts and interventions: qualitative findings from a UK study.

Virginia Sherborne (Sheffield, UK), Stephanie Ejeqi-Memeh (Sheffield, UK), Bethany Taylor (Sheffield, UK), Catriona Mayland (Sheffield, UK), Kim Balmer (Liverpool, UK), Angela Tod (Sheffield, UK)

PO-135

From research to practice: improving early-stage engagement with palliative care for patients and families living with mesothelioma.

Sarah Hargreaves (Sheffield, UK), Clare Gardiner (Sheffield, UK), Madeleine Harrison (Sheffield, UK), Bethany Taylor (Sheffield, UK), Joelle Kirby (Loughborough, UK), Donna Wakefield (North Tees and Hartlepool, UK), Leah Taylor (Loughborough, UK)

PO-139

Snapshot audit of Patient Caseload at Mesothelioma Specialist Centre and the role of the Mesothelioma UK Nurse specialist in managing these patients.

Louise Nelson, Liz Darlison, Laura Smith, Dean Fennell (Leicester, UK)

PO-142

Snapshot audit of the Mesothelioma Patient Caseload at the University Hospitals of Leicester (UHL) and the Role of the Mesothelioma UK Nurse Specialis.

Louise Nelson, Laura Smith, Liz Darlison, Dean Fennell (Leicester, UK)

PO-161

Improving Research Access for Mesothelioma Patients (IRAMP).

Simon Bolton (Huddersfield, UK)

PO-165

Rethinking continuity in primary care for people with mesothelioma.

Emilie Couchman, Steph Ejeqi-Memeh, Sarah Mitchell, Clare Gardiner (Sheffield, UK)

PO-167

Anorexia was associated with higher nodal stage in malignant pleural mesothelioma but not with survival outcomes.

Hala Aziz, Mohamed Rahouma (Cairo, Egypt)

PO-170

Providing Professional and Peer Support for Young People Living with a Diagnosis of Mesothelioma.

Julie Morton (Leicester, UK), Simon Bolton (Huddersfield, UK)

PO-171

Second- and third-line chemotherapy in the treatment of malignant pleural mesothelioma.

Güntülü Ak, Selma Metintas, Tunahan Yüce, Muzaffer Metintas (Eskisehir, Turkey)

PO-172

Spontaneous pneumothorax as a presentation of malignant pleural mesothelioma.

Adele Evans-Tomlinson, Helen Simm, Lisa Clarke, Matthew Evison, Raffaele Califano, Yvonne Summers, Eustace Fontaine, Laura Cove-Smith, Paul Taylor (Manchester, UK)

PO-173

A single-center, retrospective study of dysphagia in patients with pleural mesothelioma.

Owen D. Mitchell, Yan Che, Buerkley Opalecky, Theodore Karrison, Hedy Kindler, Monica Malec (Chicago, IL, USA)

PO-174

Perceptions and measurements of dyspnea and quality of life experienced by pleural mesothelioma patients before and after lung-sparing surgery.

Melissa Culligan (Philadelphia, PA USA), Jennifer Kleindinst (Baltimore, MD USA), Mary Regan (Baltimore, MD USA), Kim Mooney-Doyle (Baltimore, MD USA), Angela Tod (Sheffield, UK), Joseph Friedberg (Philadelphia, PA USA)

PO-175

10-year survival with non-resectable Pleural Mesothelioma T2N3M0 on platinum and pemetrexed alone with 4 times re-induction – a case report.

Cecilia Bech Horsted, Eric Santoni-Rugiu, Jens Benn Soerensen (Copenhagen, Denmark)

PO-176

Mesothelioma and Nutrition – Exploring Attitudes and Experiences of Healthcare Professionals working in a Hospital within a high incidence area of the.

Leah Taylor (Newcastle, UK)

TRACK 7: EPIDEMIOLOGY AND ASBESTOS CONTROL, INCLUDING HEALTH PROMOTION /ADVOCACY / PREVENTION SESSION.**PO-025**

Octogenarians and survival outcomes in malignant pleural mesothelioma: Analysis of SEER database.

Mohamed Rahouma (New York, USA), Anas Dabsha (New York, USA), Ihab Saad (Cairo, Egypt), Ismail A. M. H. Elkharbotly (London, UK), Mohamed Kamel (Michigan, USA), Omnia M. Korani (Cairo, Egypt), Hala Aziz (Cairo, Egypt), Abdelrahman mohamed (Cairo, Egypt)

PO-040

The Impact of Military and Civilian Health Partnership in Raising Awareness of Asbestos Exposure in Military Personnel and Veterans.

Anne Moylan (Portsmouth, UK), Liz Darlison (Leicester, UK), George Hutchinson (London, UK)

PO-092

Under declaration of mesothelioma in France to the FIVA (Fonds d'Indemnisation des Victimes de l'Amiante).

Sabine Lalliard (Montreuil, France)

PO-103

Mesothelioma in Cyprus 1999-2019, a descriptive analysis.

Oluf Dimitri Røe (Trondheim, Norway), Konstantia Achilleos (Nicosia, Cyprus), Paul Costeas (Nicosia, Cyprus), Elisavet Papağeorgiou (Cyprus), Chryso Pieridou (Nicosia, Cyprus), Ioannis Stylianou (Nicosia, Cyprus), Antri Demetriou (Nicosia, Cyprus), Vasiliki Panou (Odense, Denmark), Haris Charalambous (Nicosia, Cyprus)

PO-108

Prior radiotherapy in mesothelioma patients: an observational study.

Paul Taylor, Anna Moss, Mairead Dixon, Raffaele Califano, Yvonne Summers, Corinne Faivre-Finn, Laura Cove-Smith (Manchester, UK)

PO-126

Spatial analysis of the relationship between the density of rural population exposed to asbestos in the environment and the incidence of MM in Turkey.

Selma Metintas, Güntülü Ak, Oğuz Han Aydilek, Muzaffer Metintas (Eskisehir, Turkey)

PO-127

Treatment patterns and overall survival for patients with malignant pleural mesothelioma in Denmark between 2011–2018: a population-based cohort study.

Jens Benn Sorensen (Aarhus, Denmark), Paul Baas (Amsterdam, The Netherlands), Szimonetta Komjáthiné Szépligeti (Aarhus, Denmark), Alma B. Pedersen (Aarhus, Denmark), Soren P. Johnsen (Aalborg, Denmark), Robert Carroll (Uxbridge, UK), Minouk J. Schoemaker (London, UK), Caroline Rault (Argonay, France), Melinda Daumont (Braine-L'Alleud, Belgium), Vera Ehrenstein (Aarhus, Denmark)

PO-136

A new system of mesothelioma epidemiological surveillance in France.

Dorothee Grange (Saint-Maurice, France), Stéphane Ducamp (Bordeaux, France), Laurence Guldner (Saint-Maurice, France), Anabelle Gilg Soit Ilg (Saint-Maurice, France)

PO-140

Shipbreaking: Creating Accountability. A Follow up to our presentation at 2021 iMiG.

Steven Kazan (Oakland, CA, USA), Faith Meltzer (Oakland, CA, USA)

PO-143

Sociodemographic and quality of life analysis of a cohort of malignant pleural mesothelioma patients at the Toronto Mesothelioma Program.

Sara Shariati, Saraf Karim, Fatemeh Zaeimi, Nastaran Shokri, Penelope Bradbury, John Cho, Marc de Perrot (Toronto, Canada)

PO-145

Patients' Rights to Compensation from United States Asbestos Bankruptcy Trust Funds—Another Update.

Steven Kazan, May Wong (Oakland, CA, USA)

PO-146

A Review of the Literature on Pericardial Malignant Mesothelioma: A Follow-up.

Steven Kazan (Oakland, CA, USA), Faith Meltzer (Oakland, CA, USA)

PO-148

Evading Liability. Evading Responsibility. Dancing with Saint-Gobain.

Steven Kazan (Oakland, CA, USA), Faith Meltzer (Oakland, CA, USA)

PO-149

Medical Privacy, Genetic Testing, and Informed Consent in Asbestos Litigation.

Steven Kazan, Laurel Halbany (Oakland, CA, USA)

PO-150

Mesothelioma patient and carer experience: A Research Prioritisation Exercise.

Bethany Taylor, Stephanie Ejeji-Memeh, Holly Bachas-Brook, Madeleine Harrison, Michaela Senek, Virginia Sherborne, Emilie Couchman, Jennifer Ross, Xueming Zhang, Clare Gardiner, Angela Tod (Sheffield, UK)

TRACK 10: CLINICAL TRIALS (INCLUDING TRIALS IN PROGRESS)**PO-036**

Prevention of skin reactions related to Tumor Treating Fields (TTFields) therapy used concomitantly with chemotherapy in pleural mesothelioma.

Sara Delfanti, Giulia Gallizzi, Francesca Marengo, Iacopo Megna, Carlotta Bertolina, Giovanni Luca Ceresoli, Federica Grosso (Alessandria, Italy)

PO-073

Development of the Mesothelioma UK Clinical Trials App: a resource for patients and healthcare professionals.

Leah Taylor (Newcastle upon Tyne, UK), Liz Darlison (Leicester, UK), Faye Forde (UK)

PO-096

Long-term outcomes in two patients with pleural mesothelioma receiving Tumor Treating Fields (TTFields) therapy with pemetrexed and carboplatin.

Giovanni Luca Ceresoli (Saronno, Italy), Laura Mannarino (Milan, Italy), Federica Grosso (Alessandria, Italy)

PO-121

PEMbroliumab Plus Lenvatinib In Second And Third Line Pleural MEsotheliomA Patients: A Single Arm Phase II Study (PEMMELA): second cohort.

Cornedine J. de Gooijer, Li-Anne H. Douma, Vincent vd. Noort, Ferry Lalezari, Jeltje F. de Vries, Marrit Vermeulen, Bodien Schilder, Illia Smesseim, Paul Baas, Jacobus A. Burgers (Amsterdam, The Netherlands)

PO-128

The experience of a District General Hospital when recruiting patients from across the region into a national study within a rare cancer.

Simon Bolton (Huddersfield, UK), Sam Chan (Portsmouth, UK), Lindsay Caygill (Harrogate, UK), Nicky Thomas (Harrogate, UK), Barbara Heath (Harrogate, UK)

PO-129

A randomised phase II trial of Niraparib versus active symptom control in patients with previously treated mesothelioma.

Hill Kayleigh (Southampton, UK), Griffiths Daniel (Southampton, UK), Eminton Zina (Southampton, UK), Morgan-Fox Abigail (Southampton, UK), Nearchou Theodora (Southampton, UK), Johnson Lucy (Southampton, UK), Harding Stephanie (Southampton, UK), Poile Charlotte (Leicester, UK), Bzura Aleksandra (Leicester, UK), Spicer Jake (Leicester, UK), Nye Mavis (Southampton, UK), Cave Judith (Southampton, UK), Danson Sarah (Sheffield, UK), Toy Elizabeth (Taunton, UK), Jain Pooja (Leeds, UK), Steele Nicola (Glasgow, UK), Shaw Paul (Velindre, UK), Taylor Paul (Manchester, UK), Szlosarek Peter (London, UK), Papadatos-Pastos Dionysis (Harlow, UK), Lind Michael (Hull, UK), Dulloo Sean (Leicester, UK), Saman Harman (Medway, UK), Bajaj Amrita (Leicester, UK), Luo Jin-Li (Leicester, UK), Darlison Liz (Leicester, UK), Griffiths Gareth (Southampton, UK), Fennell Dean (Leicester, UK)

PO-166

Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso).

Crispin Hiley (London, UK), Kitty Chan (London, UK), Laura Farrelly (London, UK), Nicholas Counsell (London, UK), Kimberly Durno (London, UK), Caroline Clarke (London, UK), Clare Gardiner (Sheffield, UK), Paul Shaw (Velindre, UK), Pip Patrick (London, UK)

TRACK 11: PERITONEAL MESOTHELIOMA**PO-134**

Experiences of care and variability in patient pathways in peritoneal mesothelioma - qualitative findings from a UK study.

Samantha Westbrook (Basingstoke, UK), Stephanie Ejeji-Memeh (Sheffield, UK), Virginia Sherborne (Sheffield, UK), Clare Warnock (Sheffield, UK), Sophia Stanford (Hampshire, UK), Lynne Squibb (Southampton, UK), Carrie Twist (Manchester, UK), Clare Gardiner (Sheffield, UK)

PO-141

First success of immunotherapy to control a peritoneal mesothelioma affecting a patient with familial Mediterranean fever.

Marc POCARD (Paris, France), Lea SAVEY (Paris, France), Aimerie DE GRAMONT (Levallois-Perret, France)

PO-144

Treatment outcome in a 10-years cohort of Mesothelioma Tunica Vaginalis Testis in Denmark.

Jens Benn Sørensen, Eric Santoni-Rugiu (Copenhagen, Denmark)

TRACK 12: NURSING AND ALLIED HEALTH**PO-133**

The Changing Mesothelioma Patient Profile: implications for clinical practice and nursing care.

Angela Tod, Peter Allmark, Stephanie Ejeji-Memeh, Bethany Taylor (Sheffield, UK)

PO-137

Experience of caring for people with Mesothelioma of the Tunica Vaginalis.

Liz Darlison, Dean Fennell, Apostolos Nakas, Louise Nelson, Laura Smith (Leicester, UK)

PO-147

Achieving Equity for Mesothelioma Patients in Wales: establishing an all-Wales national Mesothelioma network.

Sarah Morgan (Carmarthenshire, UK)

Tuesday, June 27, 2023

(posters will be available for consultation throughout the day in the poster area)

TRACK 2: PATHOLOGY AND IMPROVEMENT OF (PLEURAL) MESOTHELIOMA DIAGNOSIS**PO-001****Implementation of the diagnostic algorithm for the cytological diagnosis of pleural mesothelioma.**

Greta Ali, Anello Marcello Poma, Rossella Bruno, Agnese Proietti, Iosè Di Stefano, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini (Pisa, Italy)

PO-002**Genetic Alterations and Clinical Parameters Affect Patient Survival and Programmed Death Ligand 1 (PD-L1) Expression in Mesothelioma.**

Allen C. Zhu, Jung Woo Kwon, Andrew Hermina, Owen Mitchell, Hedy Kindler, Aliya N. Husain (Chicago, IL, USA)

PO-004**Profiling of microRNAs from Serum and Pleural Effusion derived extracellular vesicles of Pleural Mesothelioma in a retrospective cohort.**

Elisabetta Casalone (Turin, Italy), Elton Jalis Herman (Turin, Italy), Alessandra Allione (Turin, Italy), Joanna Kopecka (Turin, Italy), Marika Sculco (Novara, Italy), Marta La Vecchia (Novara, Italy), Federica Grosso (Alessandria, Italy), Chiara Catalano (Turin, Italy), Giulio Ferrero (Turin, Italy), Ottavio Rena (Novara, Italy), Antonio Maconi (Alessandria, Italy), Roberta Libener (Alessandria, Italy), Serena Penpa (Alessandria, Italy), Mario Salio (Alessandria, Italy), Dario Mirabelli (Turin, Italy), Daniela Ferrante (Novara, Italy), Irma Dianzani (Novara, Italy), Chiara Riganti (Turin, Italy), Giuseppe Matullo (Turin, Italy)

PO-021**The Scottish Mesothelioma Network: Impact of a national multidisciplinary team on Overall Survival in Malignant Pleural Mesothelioma.**

Matthew Tate (Glasgow, UK), Joshua Roche (Glasgow, UK), Selina Tsim (Glasgow, UK), Katie Ferguson (Dundee, UK), Phil Reid (Edinburgh, UK), Philip Short (Dundee, UK), Mahendran Chetty (Aberdeen, UK), Carol MacGregor (Inverness, UK), Carolyn MacRae (Glasgow, UK), Laura McNaughton (Glasgow, UK), Tracy Petrie (Aberdeen, UK), Susan Smyth (Dundee, UK), Jennifer Latham (Inverness, UK), Lynne Hunter (Livingston, UK), Rocco Bilancia (Glasgow, UK), Alan Kirk (Glasgow, UK), Craig Dick (Glasgow, UK), Fiona Roberts (Glasgow, UK), Elaine MacDuff (Glasgow, UK), Jill Slavin (Glasgow, UK), Hemamalini Pitchamuthu (Glasgow, UK), Gordon W Cowell (Glasgow, UK), Simon Sheridan (Glasgow, UK), Mike Gronski (Glasgow, UK), Laura Thomson (Glasgow, UK), Colin Noble (Glasgow, UK), Clinton Ali (Glasgow, UK), Noelle O'Rourke (Glasgow, UK), Laura Kelly (Glasgow, UK), Elizabeth Sage (Inverness, UK), Fiona Thomson (Aberdeen, UK), Helen Liddicoat (Dundee, UK), Elaine Smith (Glasgow, UK), Anna Morton (Glasgow, UK), Caroline Kelly (Glasgow, UK), Kevin G Blyth (Glasgow, UK)

PO-037**Proposed Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of Consensus Statement from the International Mesothelioma Interest Group.**

Husain Aliya (Chicago, USA), David B. Chapel (Ann Arbor, USA), Richard L. Attanoos (Cardiff, UK), Mary B. Beasley, (New York, USA), Luka Brcic (Graz, Austria), Kelly J. Butnor (Vermont, USA), Lucian R. Chiriac (Boston, USA), Andrew M. Churg (Vancouver, Canada), Sanja Dacic (New Haven, USA), Françoise Galateau-Sallé (Lyon, France), Allen Gibbs (Cardiff, UK), Allen M. Gown (Vancouver, Canada), Kenzo Hiroshima (Tokyo, Japan), Yin P. Hung (Boston, USA), Sonja Klebe (Bedford Park, Australia), Thomas Krausz (Chicago, USA), Andras Khor (Jacksonville, USA), Leslie

A. Litzky (Philadelphia, USA), Alberto Marchevsky (Los Angeles, USA), Kazuki Nabeshima (Fukuoka, Japan), Andrew G. Nicholson (London, UK), Elizabeth N. Pavlisko (Durham, USA), Anja Roden (Rochester, USA), Victor L. Roggli (Durham, USA), Jennifer L. Sauter (New York, USA), Jeffrey Schulte (Madison, USA), Michael Sheaff (London, UK), William D. Travis (New York, USA), Ming-Sound Tsao (Toronto, Canada), Ann E. Walts (Los Angeles, USA), Thomas V. Colby (Scottsdale, USA)

PO-045**Exposure type affects immune-microenvironment and clinicopathological features in pleural mesothelioma: Patients with a geographical exposure could be.**

Yusuf Kahya (Ankara, Turkey), Hilal Ozakinci (Ankara, Turkey), Ayten Kayi Cangir (Ankara, Turkey), Seher Yüksel (Ankara, Turkey), Yuichiro Kai (Hiroshima, Japan), Yoshihiro Miyata (Hiroshima, Japan), Kei Kushitani (Hiroshima, Japan), Yukio Takeshima (Hiroshima, Japan), Morihito Okada (Ankara, Turkey), Serpil Dizbay Sak (Ankara, Turkey)

PO-052**Assessment of Exhaled Volatile Organic Compounds as Biomarkers for Erionite Exposure: A Comparative Study in Tuzköy Village, Cappadocia, Turkey.**

EMRi Saliha (Istanbul, Turkey), Y. Kohneshahri Matin (Ankara, Turkey), Yonar Dilek (Ankara, Turkey), Köksal Deniz (Ankara, Turkey), Tasaltın Cihat (Kocaeli, Turkey), Salih Bekir (Ankara, Turkey)

PO-060**Exploring the clinical and pathological features associated with long survival in pleural mesothelioma (PM) patients.**

Geraldine A Lynch (Bristol, UK), Yu Zhi Zhang (London, UK), Anna Morley (Bristol, UK), Ashley Brown (Bristol, UK), Emma Tucker (Bristol, UK), Louise Staddon (Bristol, UK), Nidhi Bhatt (Bristol, UK), Andrew G Nicholson (London, UK), Nick A Maskell (Bristol, UK), Anna C Bibby (Bristol, UK)

PO-062**Identification of genes associated with mesothelioma patient survival using HTG transcriptome analysis.**

Francesca Damiola (Lyon, France), Youenn Drouet (Lyon, France), Olivier Stephanov (Grenoble, France), Nolwenn Le Stang, Françoise Galateau-Sallé (Caen, France), Marie Christine Copin (Angers, France), Christine Saçan (Nantes, France), Hugues Begueret (Bordeaux, France), Armelle Foulet-Roge (Le Mans, France), Arnaud Scherpereel (Lille, France), Ruth Sequeiros (Lyon, France), Sylvie Lantuejoul (Lyon, France)

PO-085**Significance of BAP1 loss and MTAP loss in biopsy specimens of early-stage malignant pleural mesothelioma.**

Kohei Ando (Tokyo, Japan), Yukio Tsuura (Yokosuka, Japan), Takao Morohoshi (Yokosuka, Japan), Makoto Ogata (Tokyo, Japan), Ko Yokoyama (Tokyo, Japan)

PO-097**TP53 alteration is significantly more prevalent in epithelioid mesothelioma with higher nuclear grade, nuclear atypia, and mitotic count.**

Jeffrey S. Mueller, Aliya N. Husain, Allen C. Zhu, Andrew Hermina, Owen Mitchell, Hedy L. Kindler, Jung Woo Kwon (Chicago, USA)

PO-098**Stemness-related markers in diffuse malignant mesothelioma of the pleura.**

Yasuhiro Nakashima (Tokyo, Japan), Hironori Ninomiya (Koto-ku, Japan), Kentaro Inamura (Koto-ku, Japan), Masashi Kobayashi (Tokyo, Japan), Hironori Ishibashi (Tokyo, Japan), Susumu Kirimura (Tokyo, Japan), Sakai Hiroaki (Amaçasaki City, Japan), Tetsuro Yamamoto (Amaçasaki City, Japan), Kenichi Okubo (Tokyo, Japan), Yuichi Ishikawa (Koto-ku, Japan)

PO-107**Usefulness of US guided pleural biopsy in the diagnostic workflow of pleural mesothelioma.**

Jean Baptiste ASSIE (Paris, France), Helene Goussault (Créteil, France), Florent Vinas (Créteil, France), Amel Boudjemaa (Créteil, France), Valentine Bonnefoy (Créteil, France), Quentin Gibiot (Créteil, France), Gaëlle Rousseau-Bussac (Créteil, France), Isabelle Monnet (Créteil, France), Bernard Maitre (Créteil, France), Gilles Mangiapàn (Créteil, France)

PO-123**Diagnostic accuracy of ultrasound-guided pleural biopsy for the diagnosis of malignant pleural mesothelioma.**

Mohamed Redha SELMANI (Batna, Algeria)

PO-124**Medical thoracoscopy: contribution in the diagnosis of pleural pathologies.**

DABOUSSI SELSABIL, NAAROURA AMENI, MARZOUKI SAFA, AICHAOUIA CHIRAZ, MHAMDI SAMIRA, MOATEMRI ZIED (Tunis, Tunisia)

PO-125**Pleural symphysis through medical thoracoscopy: efficiency an safety.**

DABOUSSI SELSABIL, MARZOUKI SAFA, NAAROURA AMENI, AICHAOUIA CHIRAZ, MHAMDI SAMIRA, MOATEMRI ZIED (Tunis, Tunisia)

TRACK 5: SURGERY AND MULTIMODAL TREATMENT**PO-005****Salvage surgery after immunotherapy for unresectable malignant pleural mesothelioma: Case series.**

Kyoshiro Takegahara, Masaki Hashimoto, Akihiro Fukuda, Toru Nakamichi, Akifumi Nakamura, Ayumi Kuroda, Seiji Matsumoto, Nobuyuki Kondo, Seiki Hasegawa (Nishinomiya, Japan)

PO-009**Prophylactic Pedicle Latissimus Flap with Pleurectomy and Decortication for Malignant Pleural Mesothelioma.**

John Kuckelman (Augusta, GA, USA), Desiree Steimer (Boston, MA, USA), Dennis Orgill (Boston, MA, USA), Raphael Bueno (Boston, MA, USA)

PO-010**A novel surgical approach to improve visceral decortication and aerostasis after extended pleurectomy/decortication for malignant pleural mesothelioma.**

An-Lies Provoost, Andreas Bouckaert, Cedric Vanluyten, Kristiaan Nackaerts, Birgit Weynand, Christophe Deroose, Johan Coolen, Sofian Bouneb, Philippe Nafteux, Laurens J. Ceulemans (Leuven, Belgium)

PO-011**Longterm-Outcome of mesothelioma patients treated with intracavitary cisplatin-fibrin therapy after surgery - results of a phase I/II clinical trial.**

Olivia Lauk, Lisa Hofer, Ulrike Held, Nadine Bosbach, Alessandra Matter, Mayura Meerang, Michaela Kirschner, Isabelle Opitz (Zurich, Switzerland)

PO-035**Improving Malignant Pleural Mesothelioma Outcomes Through Regionalization and Multidisciplinary Care.**

Haley Tupper (Los Angeles, USA), Stephanie Ossowski (San Francisco, USA), Yun-Yi Hung (Oakland, USA), Kian Banks (Oakland, USA), Diana Hsu (Oakland, USA), Simon Ashiku (Oakland, USA), Ashish Patel (Oakland, USA), J. Marie Suga (Oakland, USA), Jeffrey Velotta (Oakland, USA)

PO-041**Final results of MesoPDT trial: intrapleural photodynamic therapy plus pleurectomy/decortication then chemotherapy in pleural mesothelioma patients.**

Scherpereel Arnaud, Munck Camille, Surmei Ecaterina, Akkad Rias, Wasielewski Eric, Dusson Catherine, Baert Gregory, Deleporte Pascal, Desbordes Jacques, Porte Henri, Mordon Serge, Vignion Anne-Sophie (Lille, France)

PO-050**Long-term survival (8 years+) in patients with RO-R1 resected pleural mesothelioma.**

Maya Jeje Schuang Lü, Eric Santoni-Rugiu, Jesper Ravn, Jens Benn Sørensen (Copenhagen, Denmark)

PO-056**Clinical characteristics of long-term survivors of malignant pleural mesothelioma.**

Masaki Hashimoto, Akifumi Nakamura, Toru Nakamichi, Ayumi Kuroda, Kyoshiro Takegahara, Akihiro Fukuda, Seiji Matsumoto, Nobuyuki Kondo, Koza Kuribayashi, Takashi Kijima, Tohru Tsujimura, Seiki Hasegawa (Nishinomiya, Japan)

PO-064**CDKN2A expression determines survival after sub-ablative irradiation and surgery in pleural mesothelioma - Long-term results from the SMART trial.**

Marc de Perrot, Amin Zia, Licun Wu, Jeffrey Man, Dorinda Mullen, Prodipto Pal, Adam C Smith, Michael Cabanero, Zhihong Yun, Fatemeh Zaeimi, Trevor Pugh, Emanuela Felley-Bosco, Ming-Sound Tsao, Penelope Bradbury, BC John Cho

PO-079**Clinical characteristics and outcomes of patients with well differentiated papillary peritoneal mesothelial tumors.**

Aguirre Nicole, Offin Michael, Mohamed Mostafa, Cercek Andrea, Morris Marty P., Sauter Jennifer L., Ladanyi Marc, Zauderer Marjorie G., Nash Garrett M. (New York City, USA)

PO-080**Median survival time of female malignant pleural mesothelioma treated by multimodality therapy with extrapleural pneumonectomy reaches 70 months.**

Kazunori Okabe, Takuya Kimura, Nao Furukawa, Hikaru Miyamoto, Kantaro Hara (Sakai-city, Japan)

PO-081**Risk factors influencing postoperative pleural empyema in patients with pleural mesothelioma after surgery - a retrospective single center analysis.**

Peter Henschke (Zurich, Switzerland), Laura Guglielmetti (Winterthur, Switzerland), Sven Hillinger (Zurich, Switzerland), Gian Marco Monsch (Zurich, Switzerland), Didier Schneiter (Zurich, Switzerland), Isabelle Opitz (Zurich, Switzerland), Olivia Lauk (Zurich, Switzerland)

PO-086**Stromal Ki67 has a predictive value in determining outcomes following extended pleurectomy/decortication.**

Kudzayi Kutuywayo, Dean A. Fennell, Apostolos Nakas (Leicester, UK)

PO-099**Outcomes of Pleurectomy Decortication in Sarcomatoid Mesothelioma.**

Moshe Lapidot, Emanuele Mazzola, Raphael Bueno (Boston, MA, USA)

PO-101**Outcomes of Neoadjuvant Therapy in Pleural Mesothelioma Patients Undergoing Pleurectomy/Decortication: A Single Center Experience.**

Yusuf Kahya, Ayten Kayi Cangir, Bülent Mustafa Yenigün, Gökhan Kocaman, Buse Mine Konuk Balci, Serkan Enön (Ankara, Turkey)

PO-115

Outcome of extended pleural decortication in combined modality treatment for malignant pleural mesothelioma: a 3-year single-centre experience.

An-Lies Provoost, Kristiaan Nackaerts, Birgit Weynand, Christophe Deroose, Johan Coolen, Arne Neyrinck, Sofian Bouneb, Philippe Nafteux, Laurens J. Ceulemans (Leuven, Belgium)

PO-116

Salvage Surgery Following Progression on Immune Check Point inhibitors for Malignant Pleural Mesothelioma.

Kudzayi Kutwayo, Dean Fennell, Apostolos Nakas (Leicester, UK)

PO-122

Effectiveness of immune checkpoint inhibitor and radiotherapy in multimodality therapy for Malignant Pleural mesothelioma.

Takao MOROHOSHI, Kohei ANDOH, Yukio TSUURA (Yokosuka, Japan)

TRACK 6: RADIATION ONCOLOGY (WITHIN MULTIMODAL TREATMENT OR NOT)

PO-169

Focal radiotherapy for oligo-progressive pleural mesothelioma: fine-tuning the optimal doses.

Giovanni Luca Ceresoli (Bergamo, Italy), Vittorio Vavassori (Bergamo, Italy), Marta Scorsetti (Milan, Italy), Davide Franceschini (Milan, Italy), Paolo Ghirardelli (Italy)

TRACK 8: IMMUNOLOGY AND IMMUNOTHERAPY: INCLUDING COMBINATION OF TREATMENTS; GENE AND CELL THERAPIES (CAR T..) AND OTHER INTRA-PLEURAL TREATMENTS.

PO-003

Vascular-remodelling radiotherapy increases the response rate to combined anti-PD-1 and anti-CTLA-4 immunotherapy.

Alistair Cook, Synat Keam, Rebecca D'Alonzo, Anna Nowak, Martin Ebert (Perth, Australia)

PO-007

Dendritic cell therapy combined with extended-Pleurectomy/Decortication in resectable mesothelioma (ENSURE trial): results first patient.

Robert A Belderbos, Luca Cantini, Michelle V Dietz, P. Martijn Koliijn, Daphne W Dumoulin, Robin Cornelissen, Koen Bezemer, Anton W Langerak, Ralph Stadhouders, Edris Mahtab, Alexander PWM Maat, Marcella Willemsen, Jan H von der Thussen, Joachim GJV Aerts (Rotterdam, The Netherlands)

PO-008

Phenotype and functional status of tumour natural killer (NK) cells in malignant pleural mesothelioma (MPM): a pilot study.

Paraskevi (Vivian) Dimou (London, UK), Reena D'Souza (London, UK), Susan Ndagire (London, UK), Annie Rose Henry (London, UK), Andrea Bille (London, UK), Evgeniy Eruslanov (Philadelphia, PA, USA), Astero Klampatsa (London, UK)

PO-016

Ipilimumab plus nivolumab for advanced mesothelioma: implementation into clinical practice.

Cheryl Ho (Vancouver, BC, Canada), Florence T.H. Wu (Vancouver, BC, Canada), Michael Humphreys (Vernon, BC, Canada), Bal Johal (Surrey, BC, Canada), Janessa Laskin (Vancouver, BC, Canada), Sanjay Rao (Kelowna, BC, Canada), Sara K. Taylor (Kelowna, BC, Canada), Ying Wang (Vancouver, BC, Canada), Christopher W. Lee (Surrey, BC, Canada)

PO-020

Nivolumab in pretreated Pleural Mesothelioma (PM): results of a retrospective study of patients treated in second or further line in Italy.

Federica Grosso (Alessandria, Italy), Stefania Crivellari (Alessandria, Italy), Sara Delfanti (Alessandria, Italy), Antonina Deangelis (Alessandria, Italy), Laura Mazzeo (Milano, Italy), Claudia Proto (Milano, Italy), Giuseppe Lorusso (Milano, Italy), Mario Occhipinti (Milano, Italy), Chiara Dellepiane (San Martino Genova), Federica Biello (Novara, Italy), Irene Alabiso (Torino, Italy), Francesco Verderame (Palermo, Italy), Roberta Gauna (Ponderano (Bi), Italy), Irene De Simone (Milano, Italy), Federica Cuppone (Rome, Italy), Sandra Petraglia (Rome, Italy), Giulia Pasello (Padua, Italy), Giovanni Luca Ceresoli (Saronno (VA), Italy), Marina Chiara Garassino (Chicago, Illinois, USA), Valter Torri (Milano, Italy)

PO-023

Radiotherapy modulates key immune markers on mesothelioma cells in a manner that is dose- and time- dependent, and variable between individuals.

Faith Chang, Synat Keam, Tracy Seymour Hoang, Jenette Creaney, Suki Gill, Anna K. Nowak, Martin Ebert, Alistair M. Cook (Perth, Australia)

PO-028

Nivolumab and ipilimumab in the real-world setting in patients with unresectable mesothelioma.

Dumoulin Daphne, Hofman Maaïke, Douma Li-Anne, Baart Sara, Cornelissen Robin, Burgers Sjaak, Aerts Joachim (The Netherlands)

PO-029

Synergistic Effects of Combining Immune Checkpoint Inhibition and Anti-Angiogenic Therapy in the Treatment of Malignant Pleural Mesothelioma.

Sophie Rovers (Antwerp, Belgium), Céline Merlin (Antwerp, Belgium), Ho Wa Lau (Antwerp, Belgium), Jonas Van Audenaerde (Antwerp, Belgium), Scott Fisher (Perth, Australia), Anna Nowak (Perth, Australia), Patrick Pauwels (Antwerp, Belgium), Filip Lardon (Antwerp, Belgium), Jan Van Meerbeeck (Antwerp, Belgium), Evelien Smits (Antwerp, Belgium), Elly Marcq (Antwerp, Belgium)

PO-032

Development of magneto-fluorescent nanoassemblies targeted to mesothelin.

Tina Briolay (Nantes, France), Judith Fresquet (Nantes, France), Damien Meyer (Marseille, France), Brigitte Kerfelec (Marseille, France), Patrick Chames (Marseille, France), Eléna Ishow (Nantes, France), Christophe Blanquart (Nantes, France)

PO-033

Development of new affinity molecules for the targeting of mesothelin.

Tina Briolay, Tacién Petithomme, Hermelyne Gravouille, Judith Fresquet, Frédéric Pécorari, Christophe Blanquart (Nantes, France)

PO-038

Tumor immune microenvironment associates with treatment response to Immune Checkpoint Therapy (ICT) in mesothelioma.

Huihua Li, Owen Mitchell, Rohail Jameel, Jeffrey Mueller, Hedy L. Kindler, Aliya N. Husain (Chicago, USA)

PO-039

Metronomic chemotherapy improves effectiveness of pleural mesothelioma immunotherapy.

Alexis Fontaine (Liège, Belgium), Mélanie Grégoire (Liège, Belgium), Roxane Terres (Liège, Belgium), Mégane Willems (Liège, Belgium), Malik Hamaidia (Liège, Belgium), Mohthash Musambil Thammitone (Liège, Belgium), Majeed Jamakhani (Liège, Belgium), Renaud Louis (Liège, Belgium), Jo Raskin (Edegem, Belgium), Vincent Heinen (Liège, Belgium), Bernard Duysinx (Liège, Belgium), Luc Willems (Liège, Belgium)

PO-044

Impairment of measles virus oncolytic activity by healthy cells depends on the type of interferon pathway defect in mesothelioma cells.

Camille Chatelain, Marion Grard, Laurine Berland, Nicolas Jouand, Judith Fresquet, Chantal Combredet, Christophe Blanquart, Nicolas Boisgerault, Elvire Pons-Tostivint, Frédéric Tangy, Jean-François Fonteneau (Nantes, France)

PO-055

Two cases of hyperprogressive diseases in pleural mesothelioma with immune checkpoint inhibitors.

Jean Baptiste (Paris, France), Gaëlle Rousseau-Bussac (Créteil, France), Florent Vinas (Créteil, France), Gilles Manqiapan (Créteil, France), Jean-Bernard Auliac (Créteil, France), Laurence Jabot (Créteil, France), Amel Boudjema (Créteil, France), Christos Chouaid (Créteil, France), Isabelle Monnet (Créteil, France)

PO-067

IMMUNOTHERAPY PLEURAL 5-ALA PDT "IMPALA" feasibility trial: intrapleural PhotoDynamic Therapy by VATS then Nivolumab in relapsing Pleural Mesothelioma

Scherpereel A, Vignon AS, Labalette M, Humez S, Surmei E, Wasielewski E, Baert G, Desbordes J, Dhalluin X, Gauvain C, Grolez G, Delhem N, Venissac N (Lille, France)

PO-075

Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors and Mesenchymal Stem Cells in an Experimental Model of Human Malignant Mesothelioma.

Shuji Kubo (Nishinomiya, Japan), Noriyuki Kasahara (San Francisco, CA, USA), Emiko Sonoda (Nishinomiya, Japan)

PO-077

Characteristics of gene expressions in peripheral blood lymphocytes in a case of malignant pleural mesothelioma with partial response to nivolumab.

Yasumitsu Nishimura (Kurashiki, Japan), Suni Lee (Kurashiki, Japan), Naoko Kumaagai-Takei (Kurashiki, Japan), Toshiyuki Kozuki (Matsuyama, Japan), Nobukazu Fujimoto (Okayama, Japan), Takemi Otsuki (Kurashiki, Japan)

PO-089

Major therapeutic response with BEVACIZUMAB in eighth-line treatment in a patient with unresectable epithelioid pleural mesothelioma (PM).

Amira Aliouat (Grenoble, France), Gérard Zalcman (Paris, France), Isabelle Federspiel (Grenoble, France), Giulia Berardi (Grenoble, France), Denis Moro-Sibilot (Grenoble, France), Anne Claire Toffart (Grenoble, France)

PO-163

Immune monitoring in malignant peritoneal mesothelioma patients treated with dendritic cell-based immunotherapy after cytoreductive surgery and HIPEC.

M. Willemsen (Rotterdam, The Netherlands), M.V. Dietz (Rotterdam, The Netherlands), K.L.A. Quintelier (Ghent, Belgium), J.P. van Kooten (Rotterdam, The Netherlands), N.L. de Boer (Rotterdam, The Netherlands), M. Vink (Rotterdam, The Netherlands), A.R.M. Brandt-Kerkhof (Rotterdam, The Netherlands), C. Verhoef (Rotterdam, The Netherlands), Y. Saeys (Ghent, Belgium), J.G.J.V. Aerts (Rotterdam, The Netherlands), S. van Gassen (Ghent, Belgium), E.V.E. Madsen (Rotterdam, The Netherlands)

TRACK 9: MESOTHELIOMA BIOLOGY (INCLUDING PRE-CLINICAL MODELS) AND NOVEL TARGETS.

PO-006

Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma.

Niki Veale (Cambridge, UK), Joanna Obacz (Cambridge, UK), Reshma Nibhani (Cambridge, UK), Taylor S. Adams (New Haven, USA), Jonas C. Schupp (Hannover, Germany), Jose A. Valer (Cambridge, UK), Jasper Flint (New Haven, USA), Giuseppe Aresu (Cambridge, UK), Aman S. Coonar (Cambridge, UK), Adam Peryt (Cambridge, UK), Giulia Biffi (Cambridge, UK), Naftali Kaminski (New Haven, USA), Hayley Francies (Cambridge, UK), Doris M. Rassl (Cambridge, UK), Matthew J. Garnett (Cambridge, UK), Robert C. Rintoul (Cambridge, UK), Stefan J. Marciniak (Cambridge, UK)

PO-014

Targeting YB-1 as a therapeutic strategy in pleural mesothelioma.

Karin Schelch (Vienna, Austria), Dominik Emminger (Vienna, Austria), Benjamin Zitta (Vienna, Austria), Thomas G Johnson (Sydney, Australia), Verena Kopatz (Vienna, Austria), Sebastian Eder (Vienna, Austria), Alexander Ries (Vienna, Austria), Alessia Stefanelli (Vienna, Austria), Petra Heffeter (Vienna, Austria), Mir A. Hoda (Vienna, Austria), Konrad Hoetzenecker (Vienna, Austria), Balazs Dome (Vienna, Austria and Budapest, Hungary), Walter Berger (Vienna, Austria), Glen Reid (Dunedin, New Zealand), Michael Grusch (Vienna, Austria)

PO-017

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.

Paternot Sabine (Brussels, Belgium), Raspé Eric (Brussels, Belgium), Meiller Clément (Paris, France), Tarabichi Maxime (Brussels, Belgium), Assié Jean-Baptiste (Paris, France), Libert Frederick (Brussels, Belgium), Rimmelink Myriam (Brussels, Belgium), Bisteau Xavier (Brussels, Belgium), Pauwels Patrick (Antwerp, Belgium), Blum Yuna (Rennes, France), Le Stang Nolwenn (Lyon, France), Tabone-Eglinger Séverine (Lyon, Poitiers, France), Galateau-Sallé Françoise (Lyon, France), Blanquart Christophe (Nantes, France), Van Meerbeeck Jan P. (Antwerp, Belgium), Berghmans Thierry (Brussels, Belgium), Jean Didier (Paris, France), Roger Pierre P. (Brussels, Belgium)

PO-018

Genome-wide copy number analysis identifies AKT as new therapeutic target for malignant pleural mesothelioma.

Claudia Kalla, Dina Mönch, Heike Horn, Sabine Bode-Erdmann, German Ott (Stuttgart, Germany)

PO-019

Primary and hTERT-immortalized mesothelioma-associated fibroblasts and mesothelial cells as new tools for mesothelioma research.

Michael Grusch, Astrid Slany, Karin Schelch, Christine Pirker, Mir A. Hoda, Blazs Dome, Walter Berger, Christopher Gerner, Klaus Holzmann, Alexander Ries (Vienna, Austria)

PO-022

Establishing mesothelioma patient-derived organoid models from malignant pleural effusion.

Ashleigh Jean Hocking, Alexandra Farrall, Daniel Thompson, Lauren Mortimer, Sonja Klebe (Adelaide, Australia)

PO-026

Molecular and functional characterization of TEAD family members in pleural mesothelioma.

Khawla BENNANI ZIATNI (Paris, France), Clément MEILLER (Paris, France), Maya ARNOULD (Paris, France), Odette DOS SANTOS (Vitry-sur-Seine, France), Samantha SCHAEFFER (Paris, France), Françoise LE PIMPEC-BARTHES (Paris, France), Jessica ZUCMAN-ROSSI (Paris, France), Marie-Claude JAURAND (Paris, France), Iris VALTINGOGER (Vitry-sur-Seine, France), Didier JEAN (Paris, France)

PO-027

Mesothelin-binding Fn3 for a novel theranostic approach against malignant pleural mesothelioma.

Margherita Piccardi (Pisa, Italy), Filomena Rea (Pisa, Italy), Roberto Silvestri (Pisa, Italy), Margherita Piccardi (Pisa, Italy), Filomena Rea (Pisa, Italy), Roberto Silvestri (Pisa, Italy), Martina Lari (Pisa, Italy), Allison R. Sirois (Northampton, MA, USA), Francesco Bartoli (Pisa, Italy), Arianna Votta (Pisa, Italy), Sara Vitolo (Pisa, Italy), Monica Evangelista (Pisa, Italy), Andrea Tavosanis (Milan, Italy), Raffaella Mercatelli (Pisa, Italy), Lorena Tedeschi (Pisa, Italy), Elisabetta Ferraro (Pisa, Italy), Paola Anna Erba (Milan, Italy), Roberto Giovannoni (Pisa, Italy), Stefano Landi (Pisa, Italy), Sarah J. Moore (Northampton, MA, USA), Martina Lari (Pisa, Italy), Allison R. Sirois (Northampton, MA, USA), Francesco Bartoli (Pisa, Italy), Arianna Votta (Pisa, Italy), Sara Vitolo (Pisa, Italy), Monica Evangelista (Pisa, Italy), Andrea Tavosanis (Milan, Italy), Raffaella Mercatelli (Pisa, Italy), Lorena Tedeschi (Pisa, Italy), Elisabetta Ferraro (Pisa, Italy), Paola Anna Erba (Milan, Italy), Roberto Giovannoni (Pisa, Italy), Stefano Landi (Pisa, Italy), Sarah J. Moore (Northampton, MA, USA)

PO-030

Loss of BAP1 influences mesothelioma cellular motility suggesting new therapeutic approaches.

Martina Tripari, Sarah E Barnett, Jenna Kenyani, Luisa Silva, Anne Herrmann, Helen Kalirai, Joseph J Sacco, Judy M Coulson (Liverpool, UK)

PO-043

Genetically Defined Mouse Models of Malignant Pleural Mesothelioma recapitulate human MPM phenotypes and response to therapy.

Pooyeh Farahmand (Glasgow, UK), Katarina Gyuraszova (Glasgow, UK), Geeshath Jayasekera (Glasgow, UK), Holly Hall (Glasgow, UK), Claire Rooney (Glasgow, UK), Ximena Raffo-Iraola (Glasgow, UK), Jennifer Doig (Glasgow, UK), Tanya Chernova (Cambridge, UK), Leo Carlin (Glasgow, UK), Rodger Duffin (Glasgow, UK), John Le Quesne (Glasgow, UK), Crispin Miller (Glasgow, UK), Kevin Blyth (Glasgow, UK), Marion MacFarlane (Cambridge, UK), Daniel J. Murphy (Glasgow, UK)

PO-046

Characterizing the vascularization patterns of mesothelioma tumor nodules in relation to histological subtypes.

Ildiko Kovacs (Budapest, Hungary), Edina Bugyik (Budapest, Hungary), Katalin Dezso (Budapest, Hungary), Julia Tarnoki-Zach (Budapest, Hungary), Elod Mehes (Budapest, Hungary), Marton Gulyas (Budapest, Hungary), Andras Czirik (Budapest, Hungary), Elisabeth Lang (Vienna, Austria), Michael Grusch (Vienna, Austria), Karin Schelch (Vienna, Austria), Balazs Hegedus (Essen, Germany), Ildiko Horvath (Budapest, Hungary), Nandor Barany (Budapest, Hungary), Zsolt Megyesfalvi (Budapest, Hungary), Anna Tisza (Budapest, Hungary), Zoltan Lohinai (Budapest, Hungary), Konrad Hoetzenecker (Vienna, Austria), Francesco Pezzella (Oxford, UK), Sandor Paku (Budapest, Hungary), Viktoria Laszlo (Budapest, Hungary), Balazs Dome (Budapest, Hungary)

PO-047

Leptospermum extract (QVO) suppresses pleural mesothelioma tumour growth in vitro and in vivo by mitochondrial dysfunction associated apoptosis.

Huikai Shi (Sydney, Australia), Le Zhang (Sydney, Australia), Ta-Kun Yu (Sydney, Australia), Ling Zhuang (Sydney, Australia), Helen Ke (Sydney, Australia), Ben Johnson (Sydney, Australia), Emma Rath (Sydney, Australia), Kenneth Lee (Sydney, Australia), Sonja Klebe (Sydney, Australia), Steven Kao (Sydney, Australia), Karl Lijun Qin (Tuggerah, Australia), Hong Ngoc Thuy Pham (Newcastle, Australia), Quan Vuong (Newcastle, Australia), Yuen Yee Cheng (Sydney, Australia)

PO-048

Autophagy-related Gene Signature Associated with Prognosis and Therapeutics in Malignant Pleural Mesothelioma.

Chengke Zhang (Jinan, China), Ning Jiang (Jinan, China), Licun Wu (Toronto, Canada), Chuanliang Peng (Jinan, China), Marc de Perrot (Toronto, Canada), Xiaogang Zhao (Jinan, China)

PO-051

Investigating the potential utility of a WEE1 inhibitor for the treatment of pleural mesothelioma.

Ben Johnson (Concord, Australia), Huaikai Shi (Concord, Australia), Helen Ke (Concord, Australia), Ling Zhuang (Concord, Australia), Yuen Yee Cheng (Sydney, Australia), Sonja Klebe (Concord, Australia), Steven Kao (Concord, Australia)

PO-054

Dysregulated microRNAs contribute to chemotherapy-resistance of pleural mesothelioma.

Michaela B. Kirschner, Fabian Schläpfer, Mayura Meerang, Isabelle Opitz (Zurich, Switzerland)

PO-061

Preclinical assessment of potential combination treatments with PARP inhibition for pleural mesothelioma.

Luca Hegedüs, Sebastian Reuter, Fabian Mairinger, Dirk Theegarten, Till Plönes, Martin Schuler, Servet Bölükbas, Clemens Aigner, Balazs Hegedüs (Essen, Germany)

PO-063

Modelling the Photodynamic Effect in 2D versus 3D Cell Cultures of Malignant Mesothelioma.

Sam Bonsall, Megan Gray, Lewis Spurrier-best, Simon Turega, Sarah Haywood-Small (Sheffield, UK)

PO-065

PD-L1 has cell autonomous functions in mesothelioma and could be an effective target beyond its role in the immune checkpoint.

Francesca Pentimalli (Casamassima, Italy), Caterina Costa (Naples, Italy), Giuseppe Portella (Naples, Italy), Fabiana Napolitano (Naples, Italy), Madhura Thadote (Campania, Italy), Luciano Mutti (L'Aquila, Italy), Antonio Giordano (Philadelphia, USA)

PO-069

Cullin4B Ubiquitin Ligase Regulates TGF- β 1 Pathway in Pleural Mesothelioma.

Mayura Meerang, Jessica Kreienbühl, Sakunthip Changkhong, Vanessa Orłowski, Michaela B. Kirschner, Isabelle Opitz (Zurich, Switzerland)

PO-070

IHC expression of VISTA and CD47 in Malignant Pleural Mesothelioma.

Mercedes Herrera-Juárez (Madrid, Spain), Álvaro C. Ucero (Madrid, Spain), Ramón Yarza (Madrid, Spain), Ana Belén Enquita (Madrid, Spain), Esther Conde (Madrid, Spain), Nuria Carrizo (Madrid, Spain), Roxana Reyes (Barcelona, Spain), Cristina Teixido (Barcelona, Spain), Igor Gómez-Randulfe, (A Coruña, Spain), Teresa Hermida (A Coruña, Spain), Noemí Requart (Barcelona, Spain), Helena Bote-de-Cabo (Madrid, Spain), Javier Baena (Madrid, Spain), Mateo Bover (Madrid, Spain), Jon Zugazagoitia (Madrid, Spain), Luis G. Paz-Ares (Madrid, Spain)

PO-072

Comparative proteome analysis of pleural fluid biomarkers taken from mesothelioma patients, non-malignant and malignant lung diseases.

Sara Zahedi (Lisbon, Portugal), Ana Sofia Carvalho (Lisbon, Portugal), Mostafa Ejtehadifar (Lisbon, Portugal), Hans C. Beck (Odense, Denmark), Paula Borralho (Lisbon, Portugal), Antonio Bugalho (Lisbon, Portugal), Rune Matthiesen (Lisbon, Portugal)

PO-074

Translational development of PLGA-encapsulated disulfide microparticles for treatment of malignant mesothelioma.

Vinodh Kannappan (Wolverhampton, UK), Kate Butcher (Wolverhampton, UK), Andrew Pollard (Wolverhampton, UK), Yoshitha Lakshmanan (Wolverhampton, UK), Karim Azar (Wolverhampton, UK), Christopher Ireson (Hatfield, UK), Saurabh Jain (Hatfield, UK), Weiquang Wang (Wolverhampton, UK)

PO-076

Can We Utilize Collagen Receptor uPARAP as a Target for Antibody-Drug Conjugates in Mesothelioma?

Pınar Çakılçaya (Copenhagen, Denmark), Kirstine Sandal Nørregaard (Copenhagen, Denmark), Eric Santoni-Rugiu (Copenhagen, Denmark), Lars H. Engelholm (Copenhagen, Denmark), Raffit Hassan (Bethesda, Maryland, USA), Niels Behrendt (Copenhagen, Denmark)

PO-078

TGF-beta signaling is associated with in vitro tumor nodule formation and patient outcome in pleural mesothelioma.

Paul Stockhammer (New Haven, USA), Júlia Tárnoki-Zách (Budapest, Hungary), Jan Schmeller (Essen, Germany), Andras Czirik (Budapest, Hungary), Fabian Mairinger (Essen, Germany), Balazs Dome (Vienna, Austria), Ildiko Kovacs (Budapest, Hungary), Jozsef Tovari (Budapest, Hungary), Christine Pirker (Vienna, Austria), Thomas Mohr (Vienna, Austria), Michael Grusch (Vienna, Austria), Walter Berger (Vienna, Austria), Clemens Aigner (Essen, Germany), Balazs Hegedus (Essen, Germany)

PO-090

3D culture as model to study Malignant Pleural Mesothelioma.

Andrea Lamarca, Alessandro Mesaglio, Rosanna Mezzapelle, Jose M Garcia-Manteiga, Massimo P. Crippa, Marco E. Bianchi, (Milan, Italy)

PO-152

The role of Exportin-1 (XPO1) in cisplatin-resistant Malignant Pleural Mesothelioma.

Harriet R. Walker, Deborah E. Crawford, Sherif El-Khamisy, Hannah L. Moody (Bradford, UK)

PO-153

Longitudinal Profiling of Fibre-induced Pre-Neoplastic Lesions and Tumours Reveal Early Molecular Changes in Sporadic Pleural Mesothelioma.

Joaquin Zacarias-Cabeza (Cambridge, UK), Tatyana Chernova (Cambridge, UK), Andrew Craxton (Cambridge, UK), Emily L. Self (Cambridge, UK), Sara Galavotti (Cambridge, UK), Xiao-Ming Sun (Cambridge, UK), Sina Beier (Cambridge, UK), Peter Greaves (Leicester, UK), Jonathan Bennett (Leicester, UK), Apostolos Nakas (Leicester, UK), Craig A. Poland (Edinburgh, UK), Anne E. Willis (Cambridge, UK), Marion MacFarlane (Cambridge, UK)

PO-154

Molecular Profiling of Asbestos-induced Sporadic Pleural Mesothelioma Development: a role for Epigenetic Mechanisms in Disease Progression.

Joaquin Zacarias-Cabeza (Cambridge, UK), Tatyana Chernova (Cambridge, UK), Sara Galavotti (Cambridge, UK), Andrew Craxton (Cambridge, UK), Pierre Cauchy (Freiburg, Germany), Sina Beier (Cambridge, UK), Ruth Spriggs (Cambridge, UK), Xiao-Ming Sun (Cambridge, UK), Fiona A. Murphy (Cambridge, UK), Emily L. Self (Cambridge, UK), Peter Greaves (Leicester, UK), Craig A. Poland (Edinburgh, UK), Anne E. Willis (Cambridge, UK), Marion MacFarlane (Cambridge, UK)

PO-155

BAP1 loss in epithelioid mesothelioma is associated with elevated ASS1 expression and resistance to pegylated arginine deiminase.

Judy M Coulson (Liverpool, UK), Sarah E Barnett (Liverpool, UK), Martina Tripari (Liverpool, UK), Jenna Kenyani (Liverpool, UK), Zohra Butt, Liverpool (Liverpool, UK), Liam Shaw (Liverpool, UK), Jan Schulze (Liverpool, UK), Rudi Grosman (Liverpool, UK), Francesca Querques (Liverpool, UK), Luisa C Silva (Liverpool, UK), Zoe Goate (Liverpool, UK), Stefan J Marciniak (Cambridge, UK), Doris M Rassl (Cambridge, UK), Michael Shackcloth (Liverpool, UK), Richard Jackson (Liverpool, UK), Lu-Yun Lian (Liverpool, UK), Peter W Szlosarek (London, UK), Joseph J Sacco (Liverpool, UK)

PO-156

An update regarding the Meso-ORIGINS study: part of the PREDICT-Meso International Accelerator.

Mark DJ Neilly (Glasgow, UK), Selina Tsim (Glasgow, UK), John MacLay (Glasgow, UK), Rocco Bilancia (Glasgow, UK), Anna Bibby (Bristol, UK), Timothy Gatheral (Morecambe, UK), Alina Ionescu (Newport, UK), Andrew Griffiths (Newport, UK), Avinash Aujayeb (Northumbria, UK), Najib Rahman (Oxford, UK), Janet Fallon (Somerset, UK), Christopher Craig (Manchester, UK), Michelle Macdougall (Salford, UK), John Corcoran (Plymouth, UK), Rakesh Panchal (Leicester, UK), Mahendran Chetty (Aberdeen, UK), Kevin Lamote (Antwerp, Belgium), Gordon Cowell (Glasgow, UK), Crispin Miller (Glasgow, UK), Robert Rintoul (Papworth, UK), Jan Van Meerbeeck (Antwerp, Belgium), Joshua Roche (Glasgow, UK), Alexandra MacPherson (Glasgow, UK), Laura Alexander (Glasgow, UK), Julie Roberts (Glasgow, UK), Jacqui Gourlay (Glasgow, UK), Joanne McGarry (Glasgow, UK), Nicola Walker (Glasgow, UK), Kevin G Blyth (Glasgow, UK)

PO-157

Long-Fibre Carbon Nanotubes induce Malignant Pleural Mesothelioma in the MexTAG Transgenic Mouse Model, replicating Asbestos-induced Mesothelioma.

Joaquin Zacarias (Cambridge, UK), Tatyana Chernova (Cambridge, UK), Andrew Craxton (Cambridge, UK), Sara Galavotti (Cambridge, UK), Xiao-Ming Sun (Cambridge, UK), Emily L. Self (Cambridge, UK), Peter Greaves (Leicester, UK), Richard A. Lake (Australia), Craig A. Poland (Edinburgh, UK), Scott A. Fisher (Australia), Anne E. Willis (Cambridge, UK), Marion MacFarlane (Cambridge, UK)

PO-158

Developing the chick chorioallantoic (CAM) xenograft model for the evaluation of new therapies for malignant pleural mesothelioma.

Sarah E Barnett, Anne Herrmann, Liam Shaw, Jan Schulze, Elisabeth N Gash, Harish Poptani, Michael Shackcloth, Joseph J Sacco, Judy M Coulson (Liverpool, UK)

PO-159

BAG2, MDK and MAD2L1 overexpressed genes in malignant pleural mesothelioma cells as selected targets for novel therapies.

Federica Morani, Luisa Bisceglia, Lara Guerrieri, Federica Gemignani, Stefano Landi (Pisa, Italy)

PO-160

A novel therapeutic combination strategy for BAP1 mutant mesothelioma.

Nick Landman (Amsterdam, the Netherlands), Danielle Hulsmann (Amsterdam, the Netherlands), Julian Puppe (Cologne, Germany), Jitendra Badhai (Amsterdam, the Netherlands), Gaurav Pandey (Amsterdam, the Netherlands), Maarten van Lohuizen (Amsterdam, the Netherlands)

PO-162

Signaling pathways analysis highlight YAP and TAZ contribution in Pleural mesothelioma.

Maya ARNOULD, Clément MEILLER, Khawla BENNANI ZIATNI, Jean Baptiste ASSIE, Arthur DUBOIS, My KHANH PHAM, Françoise LE PIMPEC-BARTHES, Jessica ZUCMAN-ROSSI, Marie-Claude JAURAND, Didier JEAN (Paris, France)

PO-168

Patient-Derived Organoid of Malignant Mesothelioma for personalized Cancer Therapy.

Luca Volpini, Federica Monaco, Marco Tomasetti, Francesca Barbisani, Gaia Gotteri, Francesca Gonnelli, Lina Zuccatosta, Lory Santarelli, Federico Mei (Ancona, Italy)

STERITALC® for Talcum Pleurodesis

Controlled particle size



STERITALC® has been the standard of care for decades.

Its safety and efficacy have been proven and extensively documented.

[visit steritalc.com](http://www.steritalc.com)

21 clinical studies
from
16 countries
including
2486 patients
in the course of
25 years



Novatech SA
capital stock: 160.000 € • 398 941 260 RCS Marseilles
TVA CEE FR59398941260 • certified according to EN ISO 13485 Jurisdictional venue / seat of the company:
Z.I. Athélia III — 1058, Voie Antiope • F—13705 La Ciotat Cedex, France
Tel. +33 (0) 442 98 15 60 • Fax +33 (0) 442 98 15 63
info@novatech.fr • www.novatech.fr

a bess group company



iMig 2023 Local, Regional, National and International supports and/or endorsements

FINANCIAL ENDORSEMENTS



ASSOCIATIVE PARTNERS



ENDORSEMENTS



The iMig congress is organized with the support of our partners



GOLD



SILVER



BRONZE



PATIENTS ARE YOUR WORK'S **PURPOSE** YOUR WORK IS THEIR **HOPE**

Since 1999, we have connected scientists and patients in our common quest to develop effective treatments for mesothelioma.

\$11.1 MILLION
 IN RESEARCH
 FUNDING

1200+
 PATIENTS/
 FAMILY MEMBERS
 HELPED
 ANNUALLY

\$22 MILLION
 FACILITATED
 DOD RESEARCH
 FUNDING

JOIN OUR NETWORK



Every day we see families devastated by mesothelioma. At Kazan Law we do everything the legal system allows to right the wrongs done to each of our clients. But our commitment doesn't end there; we stand with you in your efforts to improve treatment, and someday to find a cure.

Thirty years ago the partners at Kazan Law started the Kazan McClain Partner's Foundation; since then we have contributed almost ten million dollars in support of many mesothelioma research programs, including those at:

- » University of California San Francisco
- » Stanford University
- » University of Baltimore Maryland
- » University of Pennsylvania
- » UCLA Thoracic Surgery
- » Creighton University School of Medicine
- » University of Chicago
- » University of Houston
- » University Hospital of Pisa
- » University of Hull
- » QIMR Berghofer Medical Research Institute

Our efforts have led to many articles published by those we have supported in major peer-reviewed journals including:

- » *International Journal of Oncology*
- » *Journal of Cellular and Molecular Medicine*
- » *Oncotarget*
- » *International Journal of Molecular Sciences*
- » *Journal of Biological Chemistry*
- » *Lung Cancer*
- » *Cancer Management and Research*
- » *Journal of Medical Imaging*
- » *Cancers*
- » *Oncogenesis*
- » *Molecular Carcinogenesis*

We are pleased to announce the availability of our biennial \$100,000 iMig Research Micro-Grant Award Program, established in 2014 and offered again this year.

To apply, please send a brief email to skazan@kazanlaw.com, explaining how much money you need (from \$1,000 to \$25,000) what the funds will be spent on, and what publishable goals you hope to accomplish.